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The ability of a compound to exert its antineoplastic activity is determined by the amount 
of its accumulation inside the cell, a process largely dependent on the transporter proteins 
which are responsible for the passage of compounds into and out of the cell. The present 
study is focussed on the uptake transporter proteins; their interactions with antineoplastic 
compounds routinely used in cancer chemotherapy, and the regulation of expression of 
one such uptake transporter protein, organic cation transporter 3 (OCT3). The interactions 
of four such uptake transporters, that are predominantly expressed in liver namely, 
organic anion transporter 2 (OAT2), sodium taurocholate cotransporting polypeptide 
(NTCP), organic anion transporting polypeptides 1B1 and 1B3 (OATP1B1 and 
OATP1B3), were analysed in stably transfected human embryonic kidney cells. The 
transporter proteins were functionally characterized using [³H] model substrates and the 
uptake of this model substrate was followed in the presence of 100 µM of the 
antineoplastic compounds. The antineoplastic compounds which were able to inhibit the 
uptake of model substrate by 60% of buffer control were chosen for further analysis of 
interaction. No compound could inhibit the NTCP mediated estrone-3-sulfate uptake by 
60% of buffer control. The affinity (Ki value) of the transporter proteins for the 
compounds that inhibited the uptake of model substrate by 60% of buffer control was 
determined by Dixon-plot analysis. OAT2 was found to strongly interact with 
bendamustine, irinotecan and paclitaxel with Ki values of 43.3 µM, 26.4 µM, and 
10.4 µM, respectively. OATP1B1 interacted with vinblastine and paclitaxel, with Ki 
values of 10.2 µM and 0.84 µM, respectively. OATP1B3 interacted with chlorambucil, 
mitoxantrone, vinblastine, vincristine, paclitaxel, and etoposide with Ki values of 
37.4 µM, 3.1 µM, 18.6 µM, 17.6 µM, 1.8 µM, and 13.5 µM, respectively.  
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From the IC50 values generated, the possibility of these interactions to contribute to 
potential drug-drug interactions was calculated. Furthermore, as mentioned above, the 
regulation of expression of OCT3 in four renal carcinoma cells (A498, ACHN, 786-O, 
and LN78) with variable OCT3 expression, was analysed at the epigenetic and post-
transcriptional levels. Using inhibitors for the processes of histone deacetylation and 
DNA methylation, the contribution of these processes was validated. It was found that 
they do not account for the huge difference of expression of OCT3 found between A498 
and ACHN cells. In addition, the methylation status of the promoter region of OCT3 was 
analysed by Ion Torrent sequencing. There was no considerable difference between the 
methylation status of the promoter regions tested in the four renal carcinoma cell lines. 
The post-transcriptional regulation of OCT3 by microRNAs was also analysed. 
MicroRNAs that have the ability to bind to 3′ untranslated region of OCT3 were obtained 
from in silico prediction programs and the expression of these microRNAs was analysed 
by qRTPCR. Two microRNAs, hsa-mir-204 and hsa-mir-143, were selected as they 
showed differential expression in A498 and ACHN cells. The levels of these microRNAs 
were altered in these cells using small molecules called microRNA mimics and antimirs, 
and the expression of OCT3 was followed. However, no correlation was observed 
between the expression levels of these microRNAs and OCT3. In this direction, the 
search for potential OCT3 regulators was pursued by the next generation sequencing of 
genome wide microRNA analysis. From the results it is clear that a many microRNAs are 
differentially expressed in the four renal carcinoma cells. To make more advances in the 
search for microRNAs which are directly or indirectly involved in the regulation of 
OCT3, transcriptome analysis from the same RNA samples is being performed. This 
approach is best suited to dissect any factors involved in the transcriptional as well as 
post-transcriptional regulation of OCT3. 
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1.1. Cancer chemotherapy 
Cancer is of utmost health concerns and is one of the primary causes of deaths to 
humanity worldwide. This made cancer a hot topic of research and the scope of research 
has widened from therapy to the basic mechanisms of generation of cancer cells, 
including factors in cells which provide predisposition or risk of cancer and those which 
are responsible for suppressing the growth of such cells in vivo. However, with the 
complex ecosystem of today's world, the balance seems to have shifted towards factors 
causing the disease. Though the disease is characterized by a lot of pathways which seem 
to be commonly involved, it also has a diversity of mechanisms operating in parallel. This 
fact makes it hard to find a common treatment without understanding the origin of disease 
in detail. The discrepancies are found not only in origins but also in those processes 
which are crucial for treatment.  Cancer therapy includes methods like radiotherapy, 
chemotherapy and surgery. However, any of the above methods individually, or in 
combination, have not been largely successful so far to yield a complete recovery and, at 
the most increase, the life span of the patients for varying periods of time, depending 
upon the organ affected. Cancer chemotherapy has the advantage among the treatment 
options that the side effects of such a therapy would not, in most cases, last long. 
Compounds which are used in the treatment of cancer are referred to as antineoplastic 
compounds. Antineoplastic compounds have varying mechanisms of action, while some 
cause abnormalities in the DNA metabolism; others cause abnormalities in cytoskeletal 
processes and so on. The ability of an antineoplastic drug to exert its cytostatic effect 
depends largely on the balance between its uptake into and extrusion from the cancer 
cells. The uptake transport proteins are involved in the transport of the compounds into 
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the cells, without the involvement of a direct energy coupling, whereas the efflux 
transporters drive the compound out the cells coupled with the hydrolysis of ATP. 
1.2. Transport proteins 
The proteins involved in the transport of antineoplastic compounds are expressed on the 
surface of cells. The efflux transport proteins are grouped into the ABC (ATP binding 
cassette) superfamily of proteins which, by virtue of their ability to hydrolyze ATP, drive 
the molecules out of the cell [1]. They include the proteins P-gp (multidrug resistance 
protein, MDR1 or ABCB1), breast cancer resistance protein (BCRP) etc. These proteins 
have been a focal point of extensive research as they are shown to be key determinants of 
chemoresistance in cells [2;3]. On the other hand, a relatively less studied group of 
proteins, which also hold key to chemoresistance of a cell are the uptake transport 
proteins, grouped under the SLC superfamily. They are shown to be involved in the 
uptake of a number of foreign compounds and influence the initial stages of the 
absorption, distribution, and metabolism (ADME) of endogens and exogenous 
compounds.  
1.3. Importance of transporter proteins in metabolism of antineoplastic 
compounds 
Most of the antineoplastic compounds in the circulation exist as a protein bound fraction 
and a free fraction. The free fraction largely represents the active compound and the 
ability of the compound to exert its cytostatic effects would largely depend on the local 
concentration of its free fraction achieved in the tumor cells. This process underlines the 
importance of transporter proteins as they form a determining factor of this process, 
infact, the efficacy of an antineoplastic compound is determined by the uptake 
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transporters and efflux transporters as mentioned above [4;5]. Furthermore, abnormalities 
in the expression of many of the transporter proteins have been associated with 
discrepancies with the metabolism of an antineoplastic compound and effectiveness of a 
drug in chemotherapy. 
1.4. Uptake transporter proteins 
The uptake transporter proteins belong to a vast superfamily of proteins referred to as the 
SLC (solute carrier) superfamily which is further classified into 53 families, containing 
almost 400 genes [4]. The classification of this superfamily is based on the sequence 
similarity of the transporter proteins. The physiological role of these proteins is unrelated 
to their ability to transport exogenous molecules, suggesting that there is no specific 
family which is exclusively involved in the uptake of foreign substances. This issue is the 
basis for an increasing number of studies aimed at finding out which transporter is 
involved in the transport of which foreign compound [6-8]. It is noteworthy to mention 
here that any interaction with a foreign compound might potentially cause an alteration in 
the physiological function of that particular transporter protein and homeostasis of the 
physiologically relevant endogenous substrates. 
1.5. Liver specific uptake transporter proteins 
The uptake transport proteins expressed in the liver play a pivotal role in the body as liver 
is the organ concerned with modification and excretion of endogenous as well as 
exogenous substances including drugs and their metabolites. Hepatic excretion of drugs 
invariably involves their uptake transporter mediated absorption from the sinusoidal 
blood into the hepatocytes wherein they are metabolized and converted to a nontoxic or 
conjugated form which is excreted. The uptake transport proteins expressed in the liver 
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include organic cation transporter 1 (OCT1), organic anion transporter 2 (OAT2), OAT7, 
sodium taurocholate cotransporting polypeptide (NTCP), organic anion transporting 
polypeptide 1B1 (OATP1B1), OATP1B3, and OATP2B1. The current work deals with 
the investigation of the ability of four of these proteins, OAT2, NTCP, OATP1B1, and 
OATP1B3, to interact with some antineoplastic compounds routinely being used in 
cancer chemotherapy. 
1.5.1 Organic anion transporter 2 
The organic anion transporter 2 (OAT2), encoded by the gene SLC22A7, is involved in 
the transport of various organic substances of both endogenous and exogenous origin. It 
has been shown to be expressed predominantly in liver, and to a lesser extent in kidney, 
lung and various other tissues in humans [9;10]. Its substrates include many endogenous 
substances like cGMP, estrone-3-sulfate, dehydroepiandrosterone sulfate, prostaglandin 
E2, purine analogs, glutamate, orotic acid, uric acid, and exogenous substrates including 
tetracycline, antiviral compounds like acyclovir, ganciclovir, zidovudine, and paclitaxel 
among others [11-15]. Two splice variants have been reported for this transporter  which 
differed by 6 ntds, the shorter variant was found to be functional demonstrated by its 
ability to transport cGMP [11]. The functional splice variant was used in this study. 
1.5.2 Sodium taurocholate cotransporting polypeptide  
The sodium taurocholate cotransporting polypeptide (NTCP) encoded by the gene 
SLC10A1, is exclusively expressed in hepatocytes. NTCP is mainly involved in the 
sodium dependent uptake of bile acids and thus in the enterohepatic circulation [16]. 
Other than bile acids, its substrates include thyroid hormones, estrone-3-sulfate and drugs 
like rosuvastatin, pitavastatin [17-19]. A recent report implicated NTCP as the receptor 
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for Hepatitis B and Hepatitis D viruses, undermining its clinical importance, and hence an 
inhibitor of NTCP is of high clinical relevance [20]. 
1.5.3 Organic anion transporting polypeptides 1B1 and 1B3 
The organic anion transporting polypeptide 1B1 and 1B3 are encoded by the genes 
SLCO1B1 and SLCO1B3 genes, respectively. They are involved in the transport of a 
variety of substances, most of which are amphipathic high molecular weight compounds, 
and the list includes endogenous substances like bile salts, both conjugated as well as 
unconjugated bilirubin, leukotrienes, prostaglandins, thyroid hormones and exogenous 
compounds like statins and certain drugs [21]. Members of OATP1 family were shown to 
interact with a variety of compounds, and some of these compounds have been proven to 
be substrates of these proteins. Both these proteins are specifically expressed in the 
sinusoidal membranes of liver [22;23] and are involved in the hepatic uptake of bile salts, 
bile pigments, and also a variety of exogenous substances like rosuvastatin, pitavastatin, 
and hence, play a crucial role in xenobiotic metabolism and regulation of the cholesterol 
homeostasis. 
1.6. Interactions of transporter proteins with antineoplastic compounds 
There are various observations citing the involvement of abnormalities in the expression 
of transporters in the ineffectiveness of substrate uptake [24;25]. This makes it very 
important to know which transporter proteins are involved in the uptake and efflux of an 
antineoplastic compound. In literature, there are a lot of studies that focus on the 
interaction of antineoplastic compounds with transporter proteins. All these studies have a 
common objective of providing individual therapy which is a prerequisite in the treatment 
of a disease as complex as cancer.  
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1.7. Antineoplastic compounds used in the study and their mechanisms of 
action 
In our study we tested several antineoplastic drugs that are routinely used in the treatment 
of cancer including alkylating agents (melphalan, bendamustine, chlorambucil, 
cyclophosphamide, trofosfamide, ifosfamide, busulfan, treosulfan, and thio TEPA), 
antimetabolites (methotrexate, cytosinarabinoside, gemcitabine, 5 fluorouracil, 
fluoroadenine, cladribine, and fludarabine), intercalating agents (doxorubicin and 
mitoxantrone), topoisomerase inhibitors (irinotecan and etoposide), mitotic inhibitors 
(vinblastine, vincristine, and paclitaxel) and those having hormone receptors as targets 
(tamoxifen, prednisone, and clodronic acid). 
Alkylating agents follow the common principle of addition of alkyl groups onto the 
guanine nucleotides in DNA. This process leads to errors during replication and 
consequently the DNA repair pathways are set in to repair the damaged or altered base, 
and failure to do so leads to cell death by apoptosis. There are differences in the 
mechanism of action of alkylating agents; some compounds like melphalan, 
bendamustine, chlorambucil, cyclophosphamide, ifosfamide, and trofosfamide lead to the 
alkylation of only one guanosine residue whereas the compounds busulfan and treosulfan 
alkylate two guanosine residues causing interstrand or intrastrand crosslinks leading to 
the DNA being arrested in a locked form inaccessible for replication, forcing the cells to 
either repair or apoptosis [26-28]. The nucleoside analogs cause cytotoxicity upon 
incorporation into DNA, leading to the accumulation of DNA breaks and subsequently 
apoptosis [29;30]. 5-fluorouracil, on the other hand, inhibits the enzyme thymidylate 
synthase enzyme resulting in low levels of dTMP and this imbalance causes DNA 
damage [31]. Topoisomerases are enzymes that are crucial for the separation of DNA 
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strands during replication and transcription. The antineoplastic compounds, irinotecan 
and etoposide, inhibit these enzymes causing extensive accumulation of DNA breaks and 
consequently cell death. Similarly, the intercalating compounds doxorubicin and 
mitoxantrone also contribute to the inhibition of topoisomerases [32]. The mitotic 
inhibitors, vinblastine, vincristine, and paclitaxel alter the structural protein tubulin and 
consequently spindle dynamics, forcing the cells to arrest the cell division, and to undergo 
apoptosis [33;34]. The mechanisms of the antineoplastic compounds are diverse as 
described in this section, but this diversity is made use of in the formulation of treatment 
regimens involving a combination of the compounds to achieve an effective means to 
treat various types of cancer as listed below. Furthermore, the success of a treatment 
regimen depends on the functional expression of the corresponding uptake transport 
proteins. 
1.8. Therapeutic uses of antineoplastic compounds used in the study 
Many of these compounds are being used either alone or in combination as front line 
drugs in chemotherapy of various cancers. A summary of the studies that explore the 
therapeutic potential of these compounds in clinical trials of specific malignancies and 
relevant literature is provided in Table 1.1.  
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Compound Type of cancer References 
Alkylating agents 
Melphalan multiple myeloma, retinoblastoma [35;36] 
Bendamustine 
chronic lymphocytic leukemia,  
Non-Hodgkin Lymphoma 
[37] 
Chlorambucil chronic lymphocytic leukemia [38;39] 
Cyclophosphamide breast cancer, B-cell lymphoma [40-43] 
Trofosfamide non-small cell lung cancer [44] 
Ifosfamide non-small cell lung cancer, anal cancer [45;46] 
Busulfan leukemia [47] 
Treosulfan Malignant melanoma, uveal melanoma [48;49] 
thioTEPA Acute leukemia [50] 
Antimetabolites 
Methotrexate 




Acute myeloid leukemia, B-cell 
lymphoma, follicular lymphoma 
[43;53-55] 
Gemcitabine Pancreatic cancer, renal cell carcinoma [45;48;49;56;57] 
5-Fluorouracil  Pancreatic cancer, colorectal cancer [58;59] 
Fluoroadenine   
Fludarabine Chronic lymphocytic leukemia  [60] 
Cladribine Hairy cell leukemia [61;62] 
Intercalating agents 
Doxorubicin 
breast cancer, bladder cancer, renal cell 
carcinoma 
[41;51;57] 
Mitoxantrone Acute myeloid leukemia [54] 
Mitotic inhibitors 
Vinblastine Bladder cancer [51] 
Vincristine Large B-cell lymphoma [43] 
Paclitaxel Pancreatic cancer [63] 
Topoisomerase inhibitors 
Irinotecan  Pancreatic cancer, colorectal cancer [58;59] 
Etoposide T cell lymphoma, [52] 
Hormone receptor targeters 
Prednisone Follicular lymphoma [55] 
Clodronic acid Malignant bone metastases [64] 
Tamoxifen breast cancer [41] 
Table 1.1 Antineoplastic compounds and their therapeutic uses. 
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1.9. Factors effecting impact of transporter proteins on chemotherapy 
There are two main factors which cause considerable variability in the effect of transport 
proteins on chemotherapy. One of the factors is the widely studied phenomenon of drug-
drug interactions. It originates in combinatorial chemotherapies wherein the interaction of 
the first drug with its transporter causes changes in the effectiveness of a second drug, 
either decreasing or increasing the bioavailability of the second drug and is associated 
with ineffective drug therapy or drug mediated cytotoxicity, respectively. There have 
been a lot of incidences of drug-drug interactions mediated by the OATP and OCT 
transporters [65]. Since drug-drug interactions can lead to drastic effects during 
chemotherapy, many models have been put forward which would predict the possibility 
of drug-drug interactions. Some of the models take into account the interactions of the 
transporter proteins with the compounds in vitro, specifically, the affinity of a transporter 
protein for the compounds in question [66-69]. The other factor is the alteration in the 
transport of the antineoplastic compound by the transporter protein. This may arise due to 
abnormalities in the localization of the protein on the membrane or an aberration in the 
expression of the transporter protein leading to a loss of its function or specificity for the 
compound. There are a myriad of mechanisms that influence the expression of a gene 
operating at various levels such as genetic, epigenetic, transcriptional, post-transcriptional 
and post-translational levels. 
1.9.1 Regulation of expression of genes at genetic and epigenetic levels 
Since transporter genes are physiologically important and are at the forefront of cancer 
chemotherapy, a small change in the nucleotide sequence might cause a magnified effect. 
Such changes were characterized for many genes as single nucleotide polymorphisms 
(SNPs) which might lead to the incorporation of a different amino acid into the protein. A 
                                                                                                                        Introduction 
10 
 
lot of such changes have been mentioned for many transport genes, which were 
associated with altered substrate recognition or transport [25;70;71]. Normally, DNA is 
closely bound together and wrapped around histone proteins to form structures called 
nucleosomes. For the expression of genes, the DNA needs to be made accessible to the 
synthesizing machinery; a process achieved by chemical modifications on histones. The 
most common modifications of histones are methylation and acetylation brought about by 
the histone methyl transferases and histone acetyl transferases. Methylation of histones 
can be of varied extents such as mono, di or tri-methylation, can occur on the same lysine 
residue and each one of these methylated states can have a different function. However, 
acetylation invariably leads to only one conclusion, the conversion of a dense 
heterochromatin to a loosely bound euchromatin. This happens by virtue of the negatively 
charged acetyl groups disturbing the interactions between positively charged (lysine and 
arginine) histone proteins and the negative phosphodiester DNA backbone, thus 
providing access to the synthesizing machinery. The reversal of these processes is 
performed by the enzymes histone demethylase and histone deacetylase. Histone 
deacetylases remove the acetyl residues on the lysine residues of histones making them 
wound back to DNA converting it into densely packed complex as represented in fig. 1.1 
[72-74]. In addition to the contribution of these modifications to differential expression of 
genes, investigations revealed that they might be associated with the development of 
cancer by altering the expression of tumor suppressor genes. In addition to these 
modifications on histone proteins, modifications also occur on DNA as methylation. The 
process of methylation occurs on CpG sites and is brought about by the enzyme DNA 
methyltransferase. These mechanisms are topics of intense research as many studies 
highlighted the role of them in carcinogenesis.  




Figure 1.1 Epigenetic regulation of a gene 
Proteins involved in the transcriptional activation and repression of a gene. Transcription factors 
(TF), co-activators (CO-ACT), histone acetyltransferase (HAT), lysine 4 histone 
methyltransferase (K4 HMT), TATA binding protein (TBP), TBP-associated factor (TAF) and 
RNA polymerase II (RNA-PII) are associated with transcriptional activation. DNA 
methyltransferase (DNMT), methyl-binding domain protein (MBD), heterochromatin protein 1 
(HP1), histone 3 lysine 9 (K9 HMT), chromatin assembly factor-1 (CAF-1), histone deacetylases 
(HDAC), and co-repressor (CO-REP) are associated with transcriptional repression [74]. 
 
Molecules that could inhibit the above mentioned processes were used to study the 
mechanistic details of the epigenetic modifications and to cause changes leading to arrest 
the growth of cancer cells. Valproic acid is a compound that inhibits histone deacetylase 
enzyme, and has been extensively studied for its antineoplastic properties [75-78].  




Figure 1.2 Impact of acetylation of histones on transcription  
Equilibrium between acetylation and deacetylation effects the transcription of a gene. The 
acetylation of lysine (K) residues by histone acetyltransferase (HAT) and the selective removal of 
these acetyl groups by histone deacetylase (HDAC) results in an appropriate level of acetylation 
of histones which leads to the formation of a proper DNA-chromatin complex associated with 
transcription of selected genes (a). Inhibition of the deacetylation process leads to increased 
transcription (b) [79]. 
Similarly, a nucleoside analogue of cytidine, 5-azacytidine, has been found to be 
functionally active against DNA methylation process by inhibiting the enzyme DNA 
methyltransferase [80;81]. Azacytidine is converted to the compound 5-aza-2′-deoxy-
cytidine (decitabine) which is the active compound responsible for this activity.  




Figure 1.3 Inhibition of DNA methylation by 5-aza-2′-deoxy-cytidine (AZA-CdR) 
 Demethylation of a gene caused by inhibition of DNA methyltransferases (DNMTs) by 5-aza-2′-
deoxy-cytidine (AZA-CdR) leads to the recruitment of proteins involved in gene reactivation such 
as the histone variant H2A.Z. H2A.Z recruitment at promoter regions is performed by the Snf2-
related CBP activator protein (SRCAP) complex [82].   
Apart from the methylation patterns on the whole DNA, methylation occurring 
specifically at the promoter region has been shown to effect the expression of a gene. 
Hypermethylation of promoter regions has been associated with lower expression of the 
gene [83-85]. Infact, the methylation patterns were found to be altered in cancer, wherein 
hypomethylation was observed in sequences of most of the genome while the genes 
involved in regulating processes crucial for normal growth patterns like cell cycle were 
effectively silenced by hypermethylation [86].  
Such mechanisms have been reported to influence the uptake of therapeutically important 
molecules. Promoter methylation was reported to influence the expression of the uptake 
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transporter organic cation/carnitine transporter 2 (OCTN2) [87]. Similarly, DNA 
methylation repressed the promoter activity of organic anion transporter 3 (OAT3) [88].  
1.9.2 Transcriptional regulation of gene expression 
Epigenetic level of regulation of gene expression is followed by the transcriptional level, 
many times as a consequence of changes at the epigenetic level. As described above, 
conversion of a closed chromatin to an open one in most cases is followed by binding of 
proteins of the transcription machinery. Transcription factors are small proteins that bind 
to specific regions in the DNA around the start site of transcription. They are classified 
based on the sequences they recognize and bind to, and on the basis of their protein 
structure. They bind to sequences such as promoters, activators or silencers and this 
binding induces or hinders the formation of an active transcription complex [89-91]. 
Deviations in this tightly controlled mechanism have been implicated in various diseases 
including cancer [92]. The involvement of a lot of factors in contributing to the 
expression of a gene upon diverse stimuli made them one of the strategies for cancer 
treatment [93]. The involvement of transcription factors in the regulation of uptake 
transporters is a topic of intense research. Organic cation transporter 1, organic anion 
transporters 1 and 2 were shown to be activated by hepatocyte nuclear factor-4α (HNF-
4α) [94-96]. Similarly the organic anion transporters 5 and 7 were activated by HNF-1α 
[97]. The transcription factor BCL6 was found to activate the expression OAT2 [98]. 
1.9.3 MicroRNA based regulation of gene expression 
At the post-transcriptional level, the level and translation of the messenger RNA are 
greatly influenced by a group of non-coding RNAs referred to as microRNAs. 
MicroRNAs are transcribed either from their own discrete genes or generated during the 
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splicing of the messenger RNAs [99]. There are multiple pathways of microRNA 
biogenesis including the canonical and noncanonical pathways. The microRNAs are 
transcribed as pri-microRNAs in the canonical pathway which undergo processing by 
Drosha and other proteins to become pre-microRNAs containing a stem-loop structure 
and are exported to the cytoplasm. These immature microRNAs are bound by Dicer and 
other proteins, culminating in the formation of a mature RNA induced silencing complex 
(RISC) [100;101].  
 
Figure 1.4 Multiple pathways of microRNA biogenesis  
MicroRNAs are transcribed in the canonical pathway as primary microRNAs (pri-miRNA) with a 
cap, stem-loop and poly(A) tail. They are converted into pre-miRNA by the microprocessor 
complex (Drosha, DGCR8) in the nucleus and exported into the cytoplasm wherein the enzyme, 
Dicer, processes it further into miRNA duplex, one strand of this duplex is loaded onto RNA  
induced silencing complex (RISC). Some microRNAs are generated directly from transcription, 
while some are generated by splicing from mirtrons (generated from introns of mRNA of other 
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genes), and exported without the involvement of processing proteins in a Drosha and DGCR8-
independent pathway. Some microRNAs are synthesized short and require additional action of a 
terminal uridylyl transferase (TUTase), a step required for efficient DICER action in TUTase 
dependent pathway. In yet another pathway independent of Dicer, mir-451 is generated as a stem-
loop structure by Drosha and processed by Ago2 and poly(A)-specific ribonuclease (PARN) 
enzyme to a mature microRNA [101]. 
The mature microRNAs in the RISC are shown to bind to the 5′ or 3′ untranslated regions  
or even in the coding regions of messenger RNAs with complete or incomplete 
complementarity and this binding either triggers the degradation of mRNA or causes 
translational repression [99;102-104]. Degradation of mRNA was found to take place in 
specialized structures called P- bodies or cytoplasmic bodies [105;106]. Alternately, 
microRNA has also been shown to upregulate translation of mRNA [107-109]. It is 
worthwhile to mention here that the effect caused by microRNA in most of the cases is 
rather fine tuning the timing and expression level of the mRNA [110]. It has been seen 
that microRNA can have more than one target messenger RNAs [111] and likewise an 
mRNA can be regulated by more than one microRNA [112]. The binding of microRNA 
to messenger RNA in most cases was reported to be with incomplete complementarity. 
This makes it difficult to pinpoint which microRNA would bind to which messenger 
RNA and this quest led to the development of prediction algorithms. Many prediction 
programs were developed after studying the observed interactions between microRNA 
seed sequence and evolutionary conserved target sequence on mRNAs and algorithms 
were developed. Some of the prediction programs routinely used include TargetScan 
[113], DIANA-microT [114], miRanda [115], and PicTar [116]. A comparison of such 
algorithms revealed the accuracy of the prediction algorithms and that some programs 
have high correlation between the predicted targets with those experimentally found [117-
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120]. Simultaneously, a number of experimental procedures were also developed and 
employed to judge the accuracy of the predictions made using in silico programs [121].   
MicroRNA based regulation of expression is an emerging field of research and studies 
focused on the impact of such a regulation on the uptake transporters and hence cancer 
chemotherapy is being currently looked into as well. The microRNA mir-195-5p was 
shown to suppress the expression of the glucose transporter GLUT3 [122]. Similarly 
microRNA miR-133 was shown to regulate the expression of GLUT4 [123]. 
1.9.4 Post-translational mode of gene regulation 
Once a protein is synthesized from messenger RNA, it often undergoes a series of 
changes including formation of a functional 3 dimensional structure with the aid of 
chaperones. Post-translational modifications confer operational regulation on a protein by 
phosphorylation, acetylation, glycosylation etc. Protein phosphorylation and 
dephosphorylation are the most common mechanisms employed by the cellular 
machinery during signal transduction. Phosphorylation, glycosylation, ubiquitination and 
other post-translational modifications have been shown to affect the function of many 
transporter proteins like OCT2, NTCP etc. [124-129]. The other area of intense research, 
involving post translational modifications and protein-protein interactions, is the 
maintenance of the transporters on the plasma membrane in structures known as lipid 
rafts. Transporter membranes were often found to be localized to specialized areas on 
plasma membrane, regions rich in sphingolipids and cholesterol called lipid rafts and 
changes in constituents of lipid rafts altered their transport activity in vitro [130;131]. 
Protein-protein interactions with adaptor proteins like PDZK2 have been implicated in 
modulation of transporter activity [132;133]. 




Figure 1.5 Post-translational modifications (PTM) of proteins 
Post-translational modifications of proteins lead to a variety of consequences such as activation, 
degradation, interaction with specific partners, either protein or DNA, secretion etc. [134]. 
1.10. Regulation of organic cation transporter 3 
Organic cation transporter 3, encoded by the gene SLC22A3, is involved in the transport 
of positively charged molecules in a sodium independent manner. Considerable work has 
been done assessing the ability of OCT3 to transport physiologically and therapeutically 
important compounds. It is found to be expressed predominantly in kidney, liver, 
placenta, heart and skeletal tissues and to a lesser extent in brain and lung in humans 
[135-138]. It is involved in the uptake of physiological substances like histamine, 
serotonin, and exogenous substances like MPP, TEA, and ASP [139]. It was found to 
contribute to the regulation of salt-intake [140], uptake of the antineoplastic compounds 
melphalan, irinotecan, and vincristine [141], oxaliplatin [142], antipsychotic drug 
amisulpride [143], and also shown to interact with many antidepressants [144]. There 
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were changes in the expression of OCT3 in various carcinomas [141;145] and this factor, 
in addition to the important physiological role it plays, made the quest of mechanism of 
regulation of OCT3 expression, a matter of considerable interest. The changes in 
expression of OCT3 were observed to affect the transporter mediated accumulation of 
antineoplastic drugs in renal cell carcinoma [141].  
The contribution of single nucleotide polymorphisms [146], methylation patterns [147] 
and the effects of kinases and other proteins on the expression and function of OCT3 
were studied in detail [148-150]. However, the regulation of OCT3 by microRNAs and 
the impact of such a regulation on the function of OCT3 have not been looked into yet.  
1.11. Objectives of the thesis 
The objectives of this work are  
1) To analyze the interactions of antineoplastic compounds with the SLC transporter 
proteins specifically expressed in hepatocytes namely, organic anion transporter 2 
(OAT2), sodium taurocholate cotransporting polypeptide (NTCP), and organic anion 
transporting polypeptides 1B1 and 1B3 (OATP1B1 and OATP1B3). 
2) To find out the possible factors responsible for the variable expression of organic 
cation transporter 3 in the renal carcinoma cells A498; ACHN, 786-O, and LN78. 
 
 




Reagents for cell culture 
Poly D-lysine Sigma-Aldrich 
FBS  Gibco 
Trypsin Biochrom 
Phosphate buffered saline Biochrom 
Antibiotics 
Penicillin PAA 
Streptomycin  PAA 
Hygromycin B PAA 
Media 
Quantum 286 medium PAA 
Quantum 263 medium PAA 
DMEM HG medium Sigma-Aldrich 
RPMI-1640 medium Sigma-Aldrich 
Transport buffer (Hank’s Buffer) 
Hank’s Balanced Salt Solution (HBSS) PAA; Biochrom 
HEPES buffer Biochrom 
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[³H] labeled compounds 
[³H] 3′ - 5′ cyclic guanosine monophosphate Perkin Elmer 
 [³H] estrone 3-sulfate Perkin Elmer 
[³H] cholecystokinin octapeptide Perkin Elmer 
Rotiszint eco plus scintillation solution Carl Roth 
Compounds for HPLC analysis 
Irinotecan hydrochloride  Sigma-Aldrich 
Camptothecin TCI 
Methanol  Sigma-Aldrich 
Tetra butyl ammonium hydrogen sulfate Sigma-Aldrich 
Ammonium acetate Merck 
Kits 
RNA isolation kit Qiagen 
SuperScript reverse transcriptase Life technologies 
10 mM dNTPs Life technologies 
10 mM oligo dT Eurofins  
Complete buffer Applichem 
TaqMan Universal master mix Life technologies 
TaqMan primers Life technologies 
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mirVana microRNA isolation kit Qiagen 
microRNA reverse transcription kit Life technologies 
TaqMan Universal master mix no UNG Life technologies 
microRNA mimics and antimirs Qiagen 









Table 2.1 Primers used for amplifying promoter fragments 1 and 2 
Software used  
SigmaPlot 11 
Microsoft Excel 
MarvinSketch (version 14.7.28.0) from ChemAxon 
Reference Manager 
Primer Primer ID Sequence 
1 OCT_frag1_f AAGGTTTTGGAGAAAAGTGAGT 
2 OCT_frag1_r ACCAAACCTAATACAAACCTCC 
3 OCT_frag1_r_2 AAAACCAAACCTAATACAAACCTC 
4 OCT_frag2_f GTAAGGGTTAAGGGTTGGAG 
5 OCT_frag2_r TCCCTACCAACAACCTACTCTA 
6 OCT_frag2_r_2 ACCTACTCTACAATCAACCCCA 








































































































































































































































































































































































































































































































































































































































































































































































Table 2.2 Primers for barcoded amplification of fragment 1 
























































































































































































































































































































































































































































































































































































































































































































































Table 2.3 Primers for barcoded amplification of fragment 2 




Liquid scintillation counter TriCarb 2910TR (Perkin Elmer) 
HPLC system Agilent technologies 1100 
Nanophotometer  
Spectrophotometer GeneQuant II, Pharmacia Biotech 
Gel electrophoresis unit Biometra 
Gel documentation system Biorad Fluor-S multiplier system  
pH meter inoLab 
Circulating water bath incubator Haake 
Microplate reader Berthold Technologies Mithras LB 940 
qRTPCR system Stratagene 
Thermocycler Peltier thermocycler PTC200,                        
Bio-Rad C1000 
Ultrasonicator (degasser) L&R Ultrasonics 
Sonicator Labsonic 2000 
Centrifuges Biofuge (Heraeus) 




3.1. Cell culture 
Human embryonic cells stably transfected with organic anion transporter 2 (OAT2), 
sodium taurocholate cotransporting polypeptide (NTCP), organic anion transporting 
polypeptides 1B1 or 1B3 were cultured in DMEM high glucose medium. Renal 
carcinoma cells (RCCs) were grown in Q263 medium.  
All the cells were cultivated in an incubator maintained at 37° C with 5% CO2. At 
confluency, cells were washed with 3 mL of PBS and then incubated with 3 mL of 
trypsin-EDTA solution at 37° C for 5 min (RCCs) or for 2 min at room temperature for 
HEK based cells. The cells were pipetted into a 15 mL falcon containing 3mL of medium 
and centrifuged at 1000 RPM for 5 min at room temperature. The supernatant was 
discarded and the cells were supplemented with 1 mL of fresh medium. Depending upon 
the need they were either split for the next passage of culture or used for RNA isolation. 
For storage, cells were resuspended with ice cold medium containing 10% DMSO and 
transferred onto ice for 30 min and later stored in -80° C and liquid nitrogen. 
3.2. Substrate uptake experiments 
HEK293 cells carrying the vector alone (pcDNA) or the corresponding transporter gene 
were seeded at a density of 2 x 10
5
 cells per well in poly-D-lysine coated 24 well plates 
and grown for 72 h in Quantum 286 medium containing penicillin and streptomycin. All 
substrate uptake assays were performed at 37° C in Hank’s buffer solution containing 
Hank’s balanced salt solution and 20 mM HEPES, pH 7.4 adjusted with 1N NaOH. Prior 
to the experiment, the cells were washed twice with PBS and then incubated in Hank’s 
buffer until the start of experiment. The substrate solutions were prepared in Hank’s 
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buffer, and along with the cells, were prewarmed for 5 min at 37° C. 5 µL of the substrate 
solution was taken as a standard to calculate the specific activity of the substrate. 
After the desired time point, the uptake was terminated by washing thrice with ice cold 
PBS and the cells were lysed by incubation with 1N NaOH for 1h at room temperature. 
The lysates were transferred to scintillation vials and 2.5 ml of Rotiszint eco plus 
scintillation solution was added. The counts were obtained from a liquid scintillation 
counter TriCarb 2910TR.  Data was analyzed using Microsoft Excel and SigmaPlot 11. 
3.2.1 Time dependent uptake of [³H] labeled substrates 
The uptake of [³H] labeled substrate was followed over a period of time in Hank’s buffer 
containing a mixture of labeled and unlabeled substrate amounting to a desired 
concentration. 
3.2.2 Concentration dependent uptake of radiolabeled substrates and 
determination of affinity constants 
The uptake of radiolabeled substrate was measured at increasing concentrations of 
unlabeled substrate, and the affinity of the transporter protein for its respective substrate 
was calculated from the uptake values obtained. From three such experiments, the 
Michaelis-Menten constant, Km was calculated. 
3.2.3 Inhibition of transporter activity by antineoplastic agents 
The ability of an antineoplastic compound to inhibit the uptake of the corresponding 
substrate of the transporter protein was used as an index to find out potential interactions 
between the compound and the transporter protein. The inhibition studies were performed 
with 100 µM of the antineoplastic compounds wherein the uptake was measured with a 
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substrate concentration of 1/10
th
 of the Km value of the transporter protein for the 
corresponding substrate. 
3.2.4 Concentration dependent inhibition of uptake of substrates in the presence 
of antineoplastic compounds 
The affinity of the transporter protein for the antineoplastic compound was calculated 
from Dixon plot analysis. The uptake of the radiolabeled substrate was measured in buffer 
solutions containing two different concentrations of substrate both having identical 
concentrations of labeled substrate and an increasing amount of the antineoplastic 
compound. 
3.2.4.1 Concentration dependent inhibition of OAT2 activity by the compounds 
bendamustine, irinotecan and paclitaxel 
To determine the affinity of the transporter proteins for those antineoplastic compounds 
which inhibited the uptake of the corresponding substrate to less than 40 % of buffer 
control, the Dixon plot analysis was performed. For Dixon plot analysis of inhibition of 
OAT2 mediated uptake of [³H] cGMP, the transport was performed at two different 
concentrations of cGMP; 1 µM (10 nM [
3
H] labeled cGMP and 990 nM cold cGMP) and 
10 µM cGMP (10 nM [
3
H] labeled cGMP and 9.99 µM cold cGMP) in the presence of 
increasing concentrations of the respective cytostatic compound. The concentrations used 
for bendamustine and irinotecan were 0, 5 µM, 10 µM, 20 µM, 40 µM, 70 µM, 100 µM 
and 130 µM, and for paclitaxel, the concentrations were 0, 2.5 µM, 5 µM, 7.5 µM, 10 
µM, 12.5 µM, 15 µM and 20 µM. 
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3.2.4.2 Concentration dependent inhibition of OATP1B1 activity by vinblastine 
and paclitaxel 
The uptake of [³H] estrone-3-sulfate was measured in Hank’s buffer solution containing 
20 nM [³H] estrone-3-sulfate and either 230 nM or 2.48 µM unlabeled estrone-3-sulfate 
for 5 min in the presence of 0, 10 µM, 25 µM, 50 µM, 75 µM, 100 µM, 125 µM, and 150 
µM of vinblastine, and 0, 0.1 µM, 0.25 µM, 0.5 µM, 0.75 µM, 1 µM, 1.5 µM, and 2 µM 
of paclitaxel. 
3.2.4.3 Concentration dependent inhibition of OATP1B3 activity by antineoplastic 
compounds 
In the case of OATP1B3, the uptake of [³H] CCK-8  was monitored in Hank’s buffer 
solution containing 5 nM of [³H] CCK-8  and either 995 nM or 9.995 µM unlabeled 
CCK-8  in the presence of increasing concentration of the corresponding antineoplastic 
compound. The concentrations of 0, 10 µM, 25 µM, 50 µM, 75 µM, 100 µM, 125 µM 
and 150 µM were used for chlorambucil and vinblastine, 0, 1 µM, 2 µM, 3 µM, 4 µM, 5 
µM, 7.5 µM and 10 µM for mitoxantrone; 0, 5 µM, 10 µM, 20 µM, 40 µM, 70 µM, 100 
µM and 130 µM for vincristine, 0, 0.25 µM, 0.5 µM, 1 µM, 2 µM, 3 µM, 4 µM, and 
5 µM for paclitaxel and 0, 1 µM, 2.5 µM, 5 µM, 7.5 µM, 10 µM, 15 µM and 20 µM for 
etoposide, respectively. 
3.3. Apoptosis assay by determination of the Caspase-3 activity  
Caspases are a family of enzymes that play an important role in the complex process of 
apoptosis. Most of the antineoplastic compounds used in this study invariably lead to cell 
death by apoptosis. To find whether the strong interactions observed in cis-inhibition 
experiments are associated with to the uptake of the antineoplastic compounds into the 
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cells, a specific assay for measuring the caspase-3 activity was performed. Bendamustine 
is an alkylating agent and is known to be cause apoptosis in cells. So, an apoptosis assay 
was performed using the EnzChek Caspase 3-Assay kit as per the manufacturer’s protocol 
with some modifications.  Briefly, 2 x 10
5
 cells were seeded in 24 well plates, grown for 
72 h, and were incubated further with 100 µM bendamustine in the culture medium for 12 
h alone or in combination with 100 µM probenecid. Cells were washed in PBS, 
trypsinised, and pelleted from the spent medium, PBS wash fraction, trypsinized fraction 
and pooled together to avoid possible loss of any cells. They were lysed in 50 µl of lysis 
buffer (supplied in the kit) and subjected to a freeze thaw cycle with 5 min incubation in 
liquid nitrogen. After a spin at 5,000 rpm for 5 min, the supernatant was collected. 40 µl 
of this supernatant was added to the substrate and incubated for 20 min in a dark place. 
The remaining 10 µl was used for protein concentration determination by the Bradford 
method (Section 2.5). Fluorescence was measured in 80 µl of the 1:10 diluted product in a 
Multi-plate reader Mithras LB 940. The relative fluorescence units (RFU) were 
normalized to protein concentrations obtained from Bradford estimation and the data is 
represented as % caspase-3 activity wherein the RFU obtained with untreated pcDNA 
cells was taken as 100%. Similar assays were also conducted with irinotecan and 
paclitaxel. 
3.4. Evaluation the uptake of antineoplastic drugs in the cells by HPLC analysis  
High performance liquid chromatography is a tool used for the separation of compounds 
based on the differential properties of the compounds in interacting with substances or 
phases differently, as judged by their partition coefficients. This method is highly 
sensitive and has been successfully used as a very reliable method to quantify various 
metabolites in cells. Fluorescence based detection of compounds in HPLC analysis of cell 
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lysates has the added advantage of specificity with a minimal background contribution to 
the signal observed. 
The HPLC analysis was essentially performed as the uptake experiments mentioned 
earlier, albeit, in 100 mm plates. 3 x 10
6
 cells were seeded in poly D-lysine coated plates 
and allowed to grow to confluency. Cells were washed with PBS thrice and incubated 
with Hank’s buffer solution containing 100 µM irinotecan or a mixture of 100 µM 
irinotecan and 100 µM cGMP in a 37° C water bath for 5 min. The transport was 
terminated by placing the plates in ice cold water and then aspirating the buffer followed 
by three washes with ice-cold PBS. The cells were scrapped using 1 mL of the mobile 
phase (40% methanol: 60% 0.1 M ammonium acetate and 0.01 M TBAHS pH 5.5) 
containing 20 µM of the internal standard, camptothecin. The cell suspensions were lysed 
by sonication. 20 µL of the lysates was separated for protein estimation and the rest was 
centrifuged at 13,000 rpm at 4° C for 20 min. The supernatants were filtered through 0.2 
µM syringe filters and subjected to HPLC analysis using a Zorbax Eclipse XDB-C8 
column with 5 µL injections. Irinotecan (CPT-11) and camptothecin (CPT) were detected 
by fluorescence with excitation maximum of 355 nm and emission maximum of 515 nm 
in a mobile phase containing 40% methanol: 60% 0.1 M ammonium acetate and 0.01 M 
TBAHS pH 5.5. Standard curves were plotted using increasing concentrations of the pure 
compounds irinotecan and camptothecin. 
For measuring time dependent uptake of irinotecan, confluent cells in 100 mm culture 
dishes were washed twice with PBS and incubated in Hank’s buffer solution containing 
100 µM irinotecan for 2, 4, 6, 8 or 10 min. The buffer was removed, the cells were 
washed with ice cold PBS three times, and the cells were collected by scraping them in 1 
µL of mobile phase and analyzed as described above.  
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3.5. Determination of Protein concentration 
To normalize the amount of cell mass contributing to the observed effect, the amount of 
protein in the cell lysates was measured by Bradford method [151] with some 
modifications. Briefly, the lysates were diluted 1:20 with distilled water and 20 µl of this 
solution was added to a 96 well plate followed by the addition of 200 µl of Bradford 
reagent. The absorbance was measured at 595 nm in a Multi-plate reader Mithras LB 940. 
A standard curve was plotted from absorbance of 0, 50 µg, 75 µg, 100 µg, 150 µg, 200 
µg, 250 µg and 300 µg of BSA and the protein concentration of each test sample was 
calculated using the plotted standard curve of BSA, which is integrated in an evaluation 
table of Microsoft Excel. 
3.6. Isolation of RNA 
RNA was isolated from cells using the Qiagen RNA isolation kit or by Trizol method 
based on the experiment where it is used later.  
3.6.1 Isolation of total RNA for qRTPCR 
Qiagen kit based RNA isolation was performed for RNA that was later used in qRTPCR 
reactions. After the cells are confluent, they were pelleted as mentioned above. The cells 
were counted and 2 x 10
6
 cells were used for the process. The cells were washed twice 
with PBS and were lysed with 350 µL of lysis buffer (RLT buffer) containing 1% ß-
mercapto ethanol. The suspension was vortexed and an equal amount of 70% ethanol was 
added to it. The solution was transferred to a Qiagen filter column and was spun down at 
10,000 RPM at room temperature for 15 s. The flow through was discarded and the 
column was washed with 700 µL of wash buffer 1 (RW-1) and centrifuged at 10,000 
RPM for 15 s. It was followed by a couple of washing steps with 500 µL of wash buffer 2 
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(RW2) and spun down for 15s and 2 min, respectively. A high speed centrifugation step 
at 13,000 RPM for 1 min was applied to remove any residual wash solution. Then 30 µL 
of RNase free water was added to the center of the column and the RNA bound to the 
column was eluted during a centrifugation step of 10,000 RPM for 30 s.  
3.6.2 Isolation of total RNA using Trizol reagent 
The Trizol method of isolation of RNA was performed for genome wide sequencing of 
microRNAs in the renal carcinoma cells A498, ACHN, 786-O and LN78 cells.  Cells 
were seeded at a suitable density to yield ca. 3 x 10
6
 cells at confluency. After washing 
twice with PBS, the cells were lysed on the culture dish itself by the addition of 3 mL of 
Trizol reagent (1 mL of Trizol per 1 x 10
6
 cells). The suspension was thoroughly mixed, 
split into 2 parts into two separate 2 mL tubes and centrifuged at 11,300 RPM (12,000 x 
g) in a table top centrifuge at 4° C for 10 min. The supernatant was transferred into a 
fresh tube and left to stand at room temperature for 5 min. After 5 min, 0.3 mL of 
chloroform was added to the solution and the tubes were sealed tight and shaken 
vigorously for ca. 15 s and incubated at room temperature for a further 5 min. The 
samples were spun down at 11,300 RPM for 15 min at 4° C and the upper (aqueous) 
phase containing RNA was carefully transferred to a fresh tube without disturbing the 
white interphase (protein). The RNA present in the solution was precipitated by the 
addition of 0.75 mL of isopropanol and 1 µL of GlycoBlue (a dye used to stain the RNA 
pellet).  The samples were then incubated overnight in -20° C. They were centrifuged at 
11,300 RPM for 30 min at 4° C. The supernatant was removed by pipetting and the pellet 
was washed with 1.5 mL of 75% ethanol and centrifuged at 11,300 RPM for 5 min at 4° 
C. The wash step was repeated again and the RNA pellet obtained was dried at 37° C. 
The dry pellet was dissolved later by pipetting in 50 µL of RNase-free water. 
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3.6.3 Isolation of small RNA enriched fraction  
The small RNA fraction of the RNA pool was specifically enriched using the mirVana 
miRNA isolation kit. Confluent cells were harvested and. 2 x 10
6
 cells were separated for 
small RNA enrichment. The cells were washed twice in PBS and the cell pellets were 
resuspended in 600 µL of lysis/binding buffer supplied in the kit and thoroughly 
vortexed. To this suspension, 60 µL of microRNA homogenate additive is added and 
mixed by vortexing. After an incubation of 10 min on ice, 600 µL of acid-phenol: 
chloroform mixture was added and vortexed for 45 s to mix. The mixture was centrifuged 
at 13,000 RPM for 5 min at room temperature. The upper aqueous phase was removed 
without disturbing the lower phase into a fresh tube and the volume was measured. To 
this solution, 1/3
rd
 volume of 100% ethanol was added and thoroughly vortexed. This 
mixture was passed through a filter cartridge (700 µL at a time) and the flow through was 
collected after a centrifugation step of 10,000 RPM for 15 s. The volume of the filtrate 
was measured and 2/3
rd
 volumes of 100% ethanol was added to this mixture which 
contains the small RNAs and mixed thoroughly. This solution is passed through a second 
filter cartridge and centrifuged at 10,000 RPM for 15 s and the filtrate is discarded. Both 
the filter membranes were then washed to retrieve the larger length RNAs and the smaller 
length RNAs, respectively. The filter cartridges were washed with 700 µL of microRNA 
wash solution 1 and centrifuged for 10 s at 10,000 RPM followed by two washes with 
500 µL of wash solution 2/3 and centrifugation steps of 10,000 RPM for 10 s. The 
cartridges were given a spin to remove residual liquid and the RNA bound to the filters 
was later eluted by the addition of 100 µL of sterile water preheated to 95° C and a 
centrifugation at 13,000 RPM for 30 s. 
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3.7. Determination of concentration of RNA 
1µL of RNA was added to 9 µL of sterile water and the absorbance ratio of A260/280 and 
the concentration was measured thrice for each sample. The average of the three readings 
was calculated as the total RNA concentration for future experiments.  
3.8. Synthesis of complimentary DNA (cDNA) 
2 µg of RNA was used to prepare cDNA in a volume of 7 µL in a 200 µL PCR tube. 1µL 
of 10 mM oligo dT primer was added to the PCR tube and the mixture was subjected to 
annealing at 70° C for 10 min and then at room temperature. Meanwhile, a master mix 
was prepared with 4 µL of complete buffer containing (250 mM Tris HCl pH 8.3, 500 
mM KCl, 15 mM MgCl2, and 50 mM DTT), 1 µL of dNTPs, a volume containing 200 U 
of Superscript reverse transcriptase and 6.6 µL of sterile water to a total volume of 12 µL 
per reaction. The mixture was calculated for n + 1 reactions, where n is the number of 
reactions in the assay. The reaction mixture was mixed well by pipetting and was 
transferred to the annealing mixture and subjected to cDNA synthesis step with 
conditions of 37° C for 1h and 70° C for 10 min. The cDNA obtained was either stored in 
-20° C or used immediately for the qRTPCR reaction. 
3.9. Quantitative RT-PCR 
To measure the expression of the gene of interest, a qRTPCR reaction was performed 
using the cDNA synthesized. For all experiments aimed at finding the expression of 
OCT3, GAPDH was used as an internal control. Similarly, for experiments with objective 
of evaluating the expression status of microRNAs in the cells, the small nucleolar RNA, 
RNU43 and the microRNA hsa-mir-103 were used as internal controls. The 20 µL cDNA 
prepared was diluted to a volume of 63 µL. 1 µL of primer of the corresponding gene was 
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added to 10 µL of 10 X TaqMan master mix followed by 9 µL of the diluted cDNA. The 
reaction mixture was mixed well by pipette, briefly centrifuged and then subjected to 
qRTPCR with conditions of 50° C for 10 min, 95° C for 2 min, followed by 40 cycles of 
95° C for 15 s and 60° C for 1 min.  The plate sample values were obtained from the 
MxPro software and the data was plotted using Microsoft Excel. 
3.10. Disruption of DNA methylation using azacytidine 
Methylation of a DNA in vivo confers it to remain transcriptionally silent. There are 
many synthetic compounds which can block this process thus making the genes active; 
azacytidine is one such compound. Since the ACHN cells have less expression of OCT3, 
we performed the azacytidine based inhibition of DNA methylation on these cells, to 
check whether a transcriptional block is responsible for the low expression. 
A498 and ACHN cells were seeded in 6 well plates at a density of 3 x 10
5
 cells per well 
in 4 mL medium. After 24 h, ACHN cells were treated with 5 µM, 15 µM and 25 µM of 5 
Aza 2′ deoxy-cytidine. The medium was changed with fresh 5 Aza 2′ deoxy-cytidine 
every 24 h for a total of 72 h as the compound is highly unstable. RNA was isolated 
(Section 2.6.1) from these cells along with the untreated A498 and ACHN cells and 
cDNA was prepared, followed by a qRTPCR reaction to check the levels of expression of 
OCT3 in them (Section 2.8 and 2.9). 
3.11. Inhibition of histone deacetylase using valproic acid 
Addition of acetyl groups on the lysine residues of histones renders them less affine to the 
negative phosphodiester backbone of DNA making the gene transcriptionally active and 
reversal of this process by histone deacetylases (HDACs) leads to a transcriptionally 
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inactive state of the gene. Inhibition of histone deacetylases using compounds such as 
valproic acid has been widely used for inhibition of HDACs. 
Inhibition of histone deacetylases was performed using valproic acid in ACHN cells 
which have low OCT3 expression to check whether this results in higher expression of 
OCT3. 
A498 and ACHN cells were seeded at a density of 3 x 10
5 
cells per well in 4 mL medium 
and grown for 72 h in 6 well plates. They were incubated for a further 24 h with 0.5 mM, 
5 mM or 10 mM valproic acid. The cells were harvested and the RNA was isolated from 
them along with untreated A498 and ACHN cells. cDNA was prepared from the RNA 
and a qRTPCR reaction was performed to check the levels of expression of OCT3. 
3.12. Analysis of methylation status of promoter of SLC22A3 gene by Ion 
Torrent Sequencing 
The methylation status of a promoter is an indication of whether a gene is 
transcriptionally active or not. There are various methods to determine the methylation 
status of a gene. Recent advances in the sequencing methods led to the development of 
high throughput processes aimed to achieve high sensitivity and a simpler work flow. One 
such method is the Ion torrent sequencing. The work flow is illustrated in fig. 2.1. As 
depicted in the figure, the method involves the construction of library, followed by 
preparation of template for sequencing followed by sequencing. Prior to the construction 
of the library, the whole DNA was extracted and bisulfite treated, followed by the 
amplification of desired fragments.  




Figure 2.1 Work flow of ion torrent sequencing 
The desired fragments are amplified by emulsion PCR on the ion sphere particles and 
loaded onto a chip. During sequencing the nucleotides are sequentially flushed into and 
out of the wells. Whenever a nucleotide is added, there is a release of proton leading to 
the local change of pH that is detected by a sensor and this signal is converted into a 
digital signal. 
 
3.12.1 Extraction and bisulfite treatment of DNA 
Bisulfite treatment of total DNA is the core step of many of the procedures aimed at 
finding the methylation status of a gene, the underlying mechanism being sodium 
bisulfite treatment would convert all unmethylated cytosines into uracil. When sequenced, 
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 cells of all the four RCCs were harvested and along with the human renal cortical 
epithelial cell pellet were subjected to DNA extraction protocol using an automated 
QIAcube system. The extracted DNA was estimated in a nanophotometer. 3 µL of eluted 
DNA was used for the estimation. 1 µg of the isolated DNA was taken into a fresh tube 
and the volume was raised to 20 µL with sterile double distilled water, followed by the 
addition of 85 µL of bisulfite solution and 35 µL of DNA protect buffer.  
This mixture was vortexed and subjected to a bisulfite reaction in the QIAcube automated 
system using the protocol supplied by the manufacturer. The reaction was performed in 
the following steps; a denaturation step at 95° C for 5 min, an incubation at 60° C for 15 
min followed by another denaturation step at 95° C for 5 min followed by an incubation 
for 15 min at 60° C and then at room temperature until the next step. 
The treatment was soon followed by the cleanup procedure of bisulfite treated DNA. This 
process was performed in the QIAcube automated system under the protocol “cleanup of 
bisulfite converted DNA”. The process involves immobilizing the DNA on the Qiagen 
spin columns and removing all the reaction constituents of the bisulfite reaction. It 
involved the following steps: the bisulfite treated DNA was transferred into a 1.5 mL 
tube, followed by the addition of 250 µL of 100% ethanol and pulse vortexed for 15 s. 
After a brief spin, the mixture was passed through a MinElute DNA spin columns by 
centrifugation at full speed for 1 min. The column was washed with 500 µL of wash 
buffer (BW) followed by centrifugation at full speed for 1 min. It was followed by a 
desulfonation step wherein the columns were incubated with 500 µL of desulfonation 
buffer (BD) for 15 min at room temperature. After a full speed centrifugation step for 1 
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min, the columns were washed twice with 500 µL of BW, followed by the addition of 250 
µL of 100% ethanol to the columns and centrifuged at full speed for 1 min. The columns 
were transferred into fresh 2mL tubes and centrifuged at full speed for 1 min to remove 
any residual liquid. The DNA bound to the columns was then eluted by incubating the 
columns with 15 µL of elution buffer at room temperature for 1 min, followed by 
centrifugation of the columns at 12,000 RPM for 1 min. The eluted DNA was measured 
in a nanophotometer. 
3.12.2  Amplification of desired fragments and library preparation 
The primers were designed using the software Methyl Primer Express software. 3 µL of 
the bisulfite DNA obtained in each sample was pooled and the 15 µL was subjected to a 
gradient PCR in the range of 50° C to 70° C, with the primers designed to regions 1 and 2 
of the promoter of OCT3. The composition of the reaction mixture for 3 reactions was  
Component volume 
2X HotStart master mix 15 µL 
Forward primer (10 µM) 1.2 µL 
Reverse primer (10 µM) 1.2 µL 
Water 5.6 µL 
Bisulfite treated DNA 7 µL 
Total volume 30 µL 
 
Table 3.1 Reaction mixture of gradient PCR for amplification of promoter 
regions 1 and 2 of SLC22A3 
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10 µL of the mixture was loaded in wells and PCR reaction was performed in the 
following steps  
Step No. of cycles Temperature Duration 
Step 1 1 95° C 15 min 
Step 2 50 
95 30 s 
50-70 30 s 
65 2 min 
Step 3 1 65 1 min 
Step 4 1 8 infinite 
 
Table 3.2 PCR conditions for the amplification of promoter regions 1 and 2 
of SLC22A3 
After the reaction is completed, the PCR products were mixed with 2 µL of loading dye 
and analyzed in a 2% agarose gel. After the annealing temperature was set, 19 ng of 
bisulfite treated DNA from each sample was used to amplify the regions of interest and 
the PCR products were analyzed in a 2% agarose gel. Once all the amplified products 
were obtained, a library was prepared using 1:200 dilution of the obtained PCR product. 
Library preparation confers to the identification of each fragment of amplified DNA from 
each sample as a unique entity by the sequencer. To achieve this process, the amplified 
fragments were subjected to further PCR reactions with primers containing sequences 
called barcode and adaptor sequences. The barcode is specific for each fragment and is of 
9 or 10 nucleotides length, followed by an adaptor which is 4 nucleotides length and is 
the same sequence for all the primers which is the start point for the amplification. This 
sequence is followed by specific sequence of forward and reverse primers of fragments 1 
and 2 respectively. With the primers, an adapter PCR reaction was performed. The 
reaction mixture for this reaction for a single reaction was as follows 
 





2X HotStart master mix 15 µL 
Barcoded forward primer (10 µM) 1.2 µL 
Reverse primer (10 µM) 1.2 µL 
Water 5.6 µL 
PCR product (1:200 diluted) 7 µL 
Total volume 30 µL 
 
Table 3.3 Reaction mixture for adapter PCR 
The reaction mixture was subjected to a PCR reaction containing the following steps  
Step No. of cycles Temperature Duration 
Step 1 1 95° C 15 min 
Step 2 14 
95 30 s 
50 30 s 
65 2 min 
Step 3 1 65 5 min 
Step 4 1 8 infinite 
 
Table 3.4 PCR conditions for the amplification of barcoded fragments of 
promoter regions 1 and 2 of SLC22A3 
The products from this PCR were also analyzed on a 2% agarose gel. 
3.12.3 Quantification of library 
7 µL of the each adaptor PCR product from each fragment was separately pooled 
followed by the addition of 10 µL of loading dye and the mixture was resolved on a 2% 
agarose gel. The fragments 1 and 2 were excised from the gel and then extracted from the 
                                                                                                                     Methods 
43 
 
gel using the protocol of gel extraction of DNA in the QIAcube automated system. The 
two fragments were pooled and quantified by a quantitative PCR reaction.  
The pooled PCR products were diluted to 1:2000 and 1:20000 by the dilution scheme: 
5 µL of product + 495 µL of water                                1:100 dilution 
50 µL of 1:100 diluted product  
+ 950 µL of water                                                          1:20 dilution (used as 1:2000 
template) 
10 µL of 1:2000 template  
+ 90 µL of water                                                            1:10 dilution (used as 1:20000 
template)  
 
Using the diluted templates, the qPCR reaction was set up. The master mix was prepared 
such that each reaction was performed in triplicates along with the control library (E. coli 
DH10B control supplied with the kit). The number of reactions required was calculated 
accordingly and the reaction was set up with the following composition for 1 reaction 
Component volume 
RNase-/DNase - free water 3.86 µL 
GeneRead qPCR SYBR green Mastermix 5.68 µL 
Primer mix (10 µM) 0.45 µL 
Final volume 10 µL 
Template 3 µL 
 
Table 3.5 Reaction mixture for qPCR of amplified barcoded fragments 
The plate was sealed with an adhesive tape and the PCR was run with an SDS 2.4 
application template PCR program. Using the software the concentration of template was 
obtained which was then multiplied to the dilution factor and a factor of 0.000198 
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(corresponding to a library of average size of 300 bp) and the concentration of the library 
was obtained as ng/ µL. 
3.12.4 Ion torrent sequencing 
For the next generation sequencing protocol of Ion Torrent sequencing, the templates are 
to be adhered onto ion sphere particles which are then loaded onto a chip in which the 
sequencing by synthesis reaction is performed. 
3.12.4.1 Preparation of template positive Ion Sphere Particles (ISPs) 
The template positive ion sphere particles were prepared using the Ion One Touch system. 
The process involves an emulsion PCR where in a DNA molecule is amplified on an ion 
sphere particle in an emulsion containing all the components required for DNA synthesis, 
and multiple cycles of this process leads to clonal amplification of the desired fragments 
on the ion sphere particle. All the reactions components were added sequentially as per 
the manufacturer’s protocol as depicted in the following table 
Component volume 
Nuclease free water 280 µL 
Ion One Touch 2x reagent mix 500 µL 
Ion One Touch enzyme mix 100 µL 
Diluted library 20 µL 
Total volume 900 µL 
 
Table 3.6 Reaction mixture for emulsion PCR to prepare template positive 
ISPs 
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To this mixture, 100 µL of Ion One Touch Ion Sphere Particles were added and the 
mixture was mixed well and loaded into the sample port of the Ion One Touch reaction 
filter assembly. Then 1 mL of Ion One Touch reaction oil was added into the sample port, 
followed by the addition of another 500 µL of the oil. After performing the run, the 
samples were centrifuged and the template positive ISPs were recovered. The template 
positive ISPs were transferred into 1.5 µL LoBind tubes. The supernatant was carefully 
removed leaving a 50 µL volume and the pellets were resuspended slowly with pipette, 
pooled and the volume was raised to 1 mL with wash buffer and centrifuged at 15,500 g 
for 2.5 min removing all but 100 µL of the supernatant. The pellet was vortexed and 
proceeded further for the enrichment of the ISPs. 
3.12.4.2 Enrichment of template positive Ion Sphere Particles 
Enrichment of template positive ISPs is performed to remove the unbound DNA and 
ghost ion sphere particles (which have no DNA bound to them) and potentially enrich 
those ISPs which have amplified DNA bound to them. This is achieved by incubation of 
the template positive ISPs (with biotinylated primers) with streptavidin beads and later 
washing them off after enrichment. A fresh melt off solution was prepared by mixing 865 
µL of nuclease free water, 125 µL of 1M NaOH, and 10 µL of 10% Tween 20 solution. 
The Dynabeads MyOne streptavidin C1 beads were resuspended in 130 µL of MyOne 
beads wash solution. All the solutions were all placed in their designated wells in an 8 
well strip and the run was performed resulting in the collection of enriched template 
positive ISPs. The collected suspension was spun down at 15,500 x g for 1.5 min, washed 
with 200 µL of Ion One Touch wash solution, mixed well with pipette and centrifuged at 
15,500 x g for 1.5 min. After making sure that there are no beads left, the supernatant was 
removed leaving 10 µL of it with the pellet. The volume was raised to 100 µL with Ion 
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One Touch wash solution and the pellet was resuspended and ready to be loaded onto the 
chip for the run. 
3.12.4.3 Sequencing the template positive Ion Sphere Particles 
Meanwhile, the Ion Torrent PGM sequencer was initialized as per the manufacturer’s 
instructions. Half of the volume of obtained enriched template positive ISPs was 
transferred to a fresh 0.2 mL tube followed by the addition of 5 µL of control Ion Sphere 
Particles. The solution was centrifuged at 15,500 x g for 2 min and the supernatant was 
removed leaving 3 µL with the pellet. 3 µL of sequencing primer was added and the 
pellet was suspended with pipette. The tube was placed in a thermocycler and a run was 
performed with 95° C for 2 min and 37° C for 2 min. Meanwhile, a check was performed 
on the chip which is to be loaded with the template positive ISPs as per the guidelines 
provided in the protocol. To the reaction mixture, 1 µL of Ion PGM sequencing 200 v2 
polymerase was added to a final volume of 7 µL, mixed and incubated for 5 min at room 
temperature. The solution was loaded onto an Ion 314 chip at a rate of ca. 1 µL/ s and the 
chip was centrifuged for 30 s. The solution was pipetted in and out of chip, centrifuged 
and all the liquid was removed from the chip. Then the run was performed.  
3.13. Computational algorithms used to predict microRNAs binding to 3′ UTR of 
OCT3 
There are many prediction programs which predict microRNAs binding to the 3′ and 5′ 
untranslated regions (UTRs) of mRNA of gene of interest. The prediction programs used 
for data mining were PICTAR, DIANA microT V3.0, TargetScan Human V 5.2, 
microRNA.org and EIMMo. All the microRNA species which were predicted to bind to 
the 3′ UTR of OCT3 mRNA were collected as a data pool and such microRNA species 
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which were predicted by more than 2 of these programs were shortlisted for further 
experimentation. 
3.14. Statistical analysis 
All the statistical analysis was done using Microsoft Excel 2010 and SigmaPlot 11. p 
values were calculated using the paired samples student’s t test.  
3.15. Determination of molecular characteristics of the antineoplastic drugs 
using MarvinSketch software 
MarvinSketch (version 14.7.28.0), 2014, from ChemAxon (https://www.chemaxon.com) 
was used to determine the molecular characteristics of the antineoplastic compounds used 
in the study. All the molecular structures were downloaded as molfiles, available from the 
chEMBL database. The parameters obtained using the software, which recognizes 
molfiles, include polar surface area, logP value, logD value, existence of a compound in 
various ionization states, their percentages, and net charge at different pH values. 




4.1. Interaction of Organic anion transporter 2 with antineoplastic compounds 
 
Functionally characterized HEK cells stably expressing OAT2 were obtained from Dr. 
Saskia Flörl, PortaCellTec GmbH. From initial experiments conducted by PortaCellTec, 
the time of cGMP uptake chosen was 5 min and the Km value was calculated to be 101.4 
µM. So, the inhibition studies were performed wherein the uptake time was 5 min and the 
concentration of substrate was 10 µM. 
 
4.1.1 Inhibition of OAT2 mediated cGMP uptake by antineoplastic compounds 
The uptake of [
3
H] labeled cGMP into OAT2-HEK cells was measured in the presence of 
100 µM of the antineoplastic drugs for 5 min. Uptake of [³H] cGMP in the absence of any 
antineoplastic compounds was calculated to be 62.4 ± 1.3 pmol/ 5 min. This absolute 
value was regarded, in each independent experiment, as 100% and the uptake value in the 
presence of antineoplastic compounds is represented as percentage of this value. 
Significant changes were observed in the uptake of [
3
H] labeled cGMP into OAT2-HEK 
cells in the presence of many of the antineoplastic drugs tested and are presented as 
interactions with different classes of antineoplastic compounds based on their mechanism 
of action. 
4.1.1.1 Inhibition of OAT2 mediated cGMP uptake by alkylating agents 
Among alkylating agents, melphalan inhibited the uptake significantly by 20.7 ± 1.9 %, 
bendamustine by 86.7 ± 0.7 %, chlorambucil by 38.9 ± 1.2 % and busulfan by 21.7 ± 2.1 
% of its buffer control (Fig. 4.1). The compounds cyclophosphamide, trofosfamide, 
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ifosfamide, treosulfan and thioTEPA did not cause any significant change in the uptake 










Figure 4.1 Inhibition of OAT2 mediated uptake of [³H] cGMP in the presence of 
alkylating agents. The uptake of [3H] cyclic GMP was monitored in a buffer system containing 
10 nM [³H] cyclic GMP and 990 nM unlabeled cGMP in the presence or absence of 100 µM of 
the alkylating compounds in OAT2 transfected HEK cells and vector transfected HEK cells. Data 
represent mean ± SEM of 3 independent experiments with 3 repeats each. *** represents p value 
< 0.001.  
4.1.1.2 Inhibition of OAT2 mediated cGMP uptake by antimetabolites 
Among the antimetabolites, the compounds, methotrexate, gemcitabine and fluoroadenine 
reduced the uptake of OAT2 mediated uptake of [³H] cGMP significantly by 25.6 ± 2.9%, 
9.5 ± 2.3 % and 23.1 ± 1.9 % of buffer control, respectively (Fig. 4.2). The 
Uptake of [3H] cGMP (% of buffer control)
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antimetabolites cytosine arabinoside, 5-fluorouracil, fludarabine and cladribine did not 










Figure 4.2 Inhibition of OAT2 mediated uptake of [³H] cGMP in the presence of 
antimetabolites. The uptake of [3H] cGMP was monitored in a buffer system containing 
10 nM [
3
H] cyclic GMP and 990 nM unlabeled cGMP in the presence or absence of 100 µM of 
the antimetabolites in OAT2 transfected HEK cells and vector transfected HEK cells. Data 
represent the mean ± SEM of 3 independent experiments with 3 repeats each. ** represents p 
value < 0.01, *** represents p value < 0.001. 
4.1.1.3 Inhibition of OAT2 mediated cGMP uptake by intercalating agents and 
mitotic inhibitors 
Incubation of the cells with doxorubicin, mitoxantrone and vinblastine did not cause any 
significant effect on the OAT2 mediated uptake of [
3
H] cGMP whereas vincristine caused 
Uptake of [3H] cGMP (% of buffer control)
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a marginal increase of the uptake by 5.0 ± 1.5 % whereas paclitaxel caused a strong 










Figure 4.3 Inhibition of OAT2 mediated uptake of [³H] cGMP in the presence of 
intercalating agents and mitotic inhibitors. The uptake of [3H] cGMP was monitored in a 
buffer system containing 10 nM [
3
H] cyclic GMP and 990 nM unlabeled cGMP in the presence or 
absence of 100 µM of the intercalating agents and mitotic inhibitors in OAT2 transfected HEK 
cells and vector transfected HEK cells. Data represent the mean ± SEM of 3 independent 
experiments with 3 repeats each. * represents p value < 0.05, *** represents p value < 0.001. 
4.1.1.4 Inhibition of OAT2 mediated cGMP uptake by topoisomerase inhibitors 
and compounds targeting hormone receptors 
The topoisomerase inhibitors irinotecan and etoposide reduced the uptake by 87.8 ± 0.4 
% and 32 ± 1.2 % respectively. Tamoxifen caused an inhibition of OAT2 mediated 
Uptake of [3H] cGMP (% of buffer control)











                                                                                                                        Results 
52 
 
uptake of cGMP by 12.7 ± 2.2 % of buffer control while the compounds prednisone and 










Figure 4.4 Inhibition of OAT2 mediated uptake of [³H] cGMP in the presence of 
topoisomerase inhibitors and compounds acting on hormone receptor targets. The 
uptake of [
3
H] cGMP was monitored in a buffer system containing 10 nM [
3
H] cyclic GMP and 
990 nM unlabeled cGMP in the presence or absence of 100 µM of topoisomerase inhibitors and 
hormone receptor targeters in OAT2 transfected HEK cells and vector transfected HEK cells. 
Data represent the mean ± SEM of 3 independent experiments with 3 repeats of each sample. *** 
represents p value < 0.001. 
 
Uptake of [3H] cGMP (% of buffer control)
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4.1.2 Concentration dependent inhibition of antineoplastic compounds on OAT2 
mediated [³H] cGMP uptake 
In order to determine the affinity of OAT2 for selected antineoplastic drugs, which 
inhibited uptake to less than 40 % of buffer control, we employed the Dixon plot analysis. 
Measurement of the uptake of [
3
H] labeled cGMP at 1 µM and 10 µM cGMP was 
performed in the presence of increasing concentrations of the corresponding compound.  
4.1.2.1 Concentration dependent inhibition of OAT2 mediated [³H] cGMP uptake 
by bendamustine 
For measuring the affinity of OAT2 for bendamustine, the uptake was measured in the 
presence of increasing concentrations of bendamustine in the range of 0 – 130 µM. Plots 
of the reciprocal of velocity of uptake on Y axis over the concentration of the 
antineoplastic compound on X axis revealed the Ki value of OAT2 for bendamustine to be 







 Concentration of bendamustine (µM)
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Figure 4.5 Determination of Ki value of OAT2 for bendamustine by Dixon Plot 
analysis. The uptake of [3H] cyclic GMP was monitored in a buffer system containing 10 nM 
[
3
H] cGMP and 990 nM or 9.99 µM cGMP in the presence of 0, 5 µM, 10 µM, 20 µM, 40 µM, 70 
µM, 100 µM, and 130 µM bendamustine. Data are means ± SEMs of 3 independent experiments 
with three repeats of each sample. Figure is representative and the Ki value was calculated from 
three individual experiments.  
4.1.2.2 Concentration dependent inhibition of OAT2 mediated [³H] cGMP uptake 
by irinotecan 
The affinity of OAT2 for irinotecan was calculated from experiments wherein the uptake 
was measured in the presence of increasing concentrations of irinotecan in the range of 0 
– 130 µM. Plots of the reciprocal of velocity of uptake on Y axis over the concentration 
of the antineoplastic compound on X axis revealed Ki value of OAT2 for irinotecan to be 








Figure 4.6 Determination of Ki value of OAT2 for irinotecan by Dixon Plot analysis. 
The uptake of [
3
H] cyclic GMP was monitored in a buffer system containing 10 nM [
3
H] cGMP 
Concentration of irinotecan (µM)






















                                                                                                                        Results 
55 
 
and 990 nM or 9.99 µM cGMP in the presence of 0, 5 µM, 10 µM, 20 µM, 40 µM, 70 µM, 100 
µM, and 130 µM irinotecan. Data are means ± SEMs of 3 independent experiments with three 
repeats of each sample. Figure is representative and the Ki value was calculated from three 
individual experiments.  
4.1.2.3 Concentration dependent inhibition of OAT2 mediated [³H] cGMP uptake 
by paclitaxel 
The affinity of OAT2 for paclitaxel was calculated from experiments wherein the uptake 
was measured in the presence of increasing concentrations of paclitaxel in the range of 0 
– 20 µM. Plots of the reciprocal of velocity of uptake on Y axis over the concentration of 
the antineoplastic compound on X axis revealed Ki value of OAT2 for paclitaxel to be 








Figure 4.7 Determination of Ki value of OAT2 for paclitaxel by Dixon – Plot 
analysis. The uptake of [3H] cyclic GMP was monitored in a buffer system containing 10 nM 
[
3
H] cGMP and 990 nM or 9.99 µM cGMP in the presence of 0, 2.5 µM, 5 µM, 7.5 µM, 10 µM, 
12.5 µM, 15 µM, and 20 µM paclitaxel from 0 to 20 µM. Data are means ± SEMs of 3 
Concentration of paclitaxel (µM)
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independent experiments with three repeats of each sample. Figure is representative and the Ki 
value was calculated from three individual experiments.  
 
4.1.3 Evaluation of OAT2 mediated uptake of bendamustine by apoptosis  
To find out, indirectly, whether bendamustine is transported by OAT2, an enzymatic 
assay measuring the activity of caspase-3 enzyme, a key enzyme in the cascade of 
apoptosis, was performed. The assay is based on the ability of the caspase-3 enzyme in 
cell lysates to cleave the substrate bound to a fluorescent dye, releasing the fluorophore 
which was then estimated. Incubation of OAT2 expressing cells with 100 µM 
bendamustine showed an increase in the caspase-3 activity by ca. 16% of untreated 
pcDNA while the activity in control cells did not change significantly. This increase in 
caspase-3 activity was completely diminished when the bendamustine treatment was 
performed in combination with 100 µM probenecid, an OAT2 inhibitor (Fig. 4.8).  





Figure 4.8 Evaluation of OAT2 mediated apoptosis. Caspase-3 activity was monitored in 
OAT2 expressing cells and pcDNA cells incubated with 100 µM bendamustine for 12 h alone or 
in the presence of 100 µM probenecid. The relative fluorescence unit values obtained in the 
experiment were normalized with protein levels and expressed as % of the value obtained in 
control pcDNA cells. Data are means ± SEMs of two individual experiments with two technical 
repeats each. *** indicates p value < 0.001; ns - not significant. 
4.1.4 Evaluation of OAT2 mediated accumulation of irinotecan by HPLC 
analysis 
The OAT2 uptake of irinotecan was determined by HPLC analysis. A working protocol 
was established and standardized prior to the assay. The characteristic peaks for each 
compound were obtained by injections of pure substances in the same conditions of the 
experimental run. Standard curves were plotted for both irinotecan as well as 
camptothecin (internal standard) in the range of 15 pmol to 500 pmol. The results from 
three independent runs show that the retention times of irinotecan and camptothecin were 
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ca. 5.7 min and 11.6 min respectively. Using them as reference in each experiment, 
uptake amount was quantified. 
4.1.4.1 Quantitation of OAT2 mediated uptake of irinotecan 
From the standard curve, the amount of irinotecan found in lysates of OAT2 expressing 
cells was approximately 86 pmol/ 5 min which was regarded as 100%. Accumulation of 
irinotecan in mock pcDNA cells was 57.4 % ± 7.5 % of irinotecan found in OAT2 
expressing cells (Fig. 4.9). The uptake of irinotecan was strongly inhibited by 100 µM 
cGMP to 68.6 ± 12.2 % in OAT2 expressing cells whereas the irinotecan uptake was not 
significantly changed in pcDNA treated with 100 µM cGMP (49.7 % ± 12.1 %) 
confirming the cGMP induced reduction in the accumulation of irinotecan is specific to 
transport by OAT2. 
 
Figure 4.9 Evaluation of OAT2 mediated irinotecan uptake. Irinotecan uptake was 
monitored by HPLC analysis in pcDNA and OAT2 expressing cells treated with 100 µM 
irinotecan alone or in combination with 100 µM cGMP. The amount of irinotecan found was 
normalized with internal standard and as well to protein concentration and expressed as uptake 
per mg protein. Irinotecan uptake in OAT2 expressing cells treated with irinotecan alone is taken 
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as 100 % and the other conditions are represented as percentage of that value. Data are means ± 
SEMs of three individual experiments. RFU - relative fluorescence units. *** indicates p value < 
0.001; ns - not significant. 
4.1.4.2 Time dependent OAT2 mediated uptake of irinotecan 
The amount of irinotecan in the cells was analyzed in pcDNA and OAT2 cells incubated 
with 100 µM irinotecan for increasing periods of time. There was an increase both in the 
OAT2 dependent as well as nonspecific uptake into the cells, however, the OAT2 
mediated uptake was far more pronounced as can be seen from the net uptake plotted 








Figure 4.10 Evaluation of time dependent uptake of irinotecan. Irinotecan uptake was 
monitored in pcDNA and OAT2 cells after incubation with irinotecan for 2, 4, 6, 8 and 10 min. 
The uptake was normalized to the internal standard and the protein amount and the net uptake was 
calculated by subtracting the irinotecan values of pcDNA from OAT2 cells and expressed as 
relative fluorescence units (RFU)/ mg protein. 
Time (min)
























                                                                                                                        Results 
60 
 
4.1.4.3 Concentration dependent uptake of irinotecan by pcDNA and OAT2 cells 
Accumulation of irinotecan was followed by performing HPLC analyses of lysates of 
cells incubated with increasing amounts of irinotecan in Hank’s buffer solution. Similar 
to time course experiments, with increase in concentration of irinotecan in the transport 
buffer, an increase in the amount of irinotecan was observed in the lysates. The Km value 








Figure 4.11 Evaluation of concentration dependent uptake of irinotecan. Irinotecan 
uptake was monitored in pcDNA and OAT2 cells after incubation with 20 µM, 40 µM, 60 µM, 80 
µM, 100 µM, and 120 µM irinotecan for 5 min. The uptake was normalized to the internal 
standard and the protein amount, and the net uptake was calculated by subtracting the irinotecan 
values of pcDNA from OAT2 cells and expressed as relative fluorescence units (RFU)/ mg 
protein. Figure is representative of one of the experiments and the Km value was calculated from 
two such experiments. 
Concentration of irinotecan




















 = 42.37 µM 
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4.2. Interaction of sodium taurocholate cotransporting polypeptide (NTCP) 
with antineoplastic compounds 
A functional characterization of NTCP cells stably transfected into HEK cells was 
performed prior to the interaction studies of NTCP with antineoplastic compounds. 
4.2.1 Functional characterization of NTCP 
Using estrone-3-sulfate as substrate, the transporter activity of NTCP was evaluated. 
Uptake experiments were performed with [³H] estrone-3-sulfate for time dependency and 
calculation of affinity of NTCP for estrone-3-sulfate. 
4.2.1.1 Time dependent uptake of [³H] estrone -3-sulfate by NTCP expressing cells 
A time course experiment was conducted with NTCP-HEK cells and vector transfected 
HEK cells where the uptake of 1 µM estrone-3-sulfate was measured over a period of 30 
min. From the plot, 3 min was chosen as the time for further experiments as this was in 
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Figure 4.12 Time dependent uptake of NTCP mediated estrone-3-sulfate. The uptake 
of 1 µM estrone-3-sulfate containing 20 nM [
3
H] estrone-3-sulfate was monitored for 0.5, 1, 2, 3, 
5, 10, 20, and 30 min in NTCP expressing HEK cells and vector transfected HEK cells. Net 
uptake was calculated by subtracting the uptake values of control cells from NTCP expressing 
cells. Data is the means ± SEMs of triplicates obtained from three identical experiments and 
expressed as pmol/ mg of protein.  
4.2.1.2 Concentration dependent uptake of [³H] estrone-3-sulfate by NTCP 
expressing cells 
The affinity of NTCP for estrone-3-sulfate was determined by calculating the Michaelis-
Menten constant (Km). Uptake experiments in buffer containing 20 µM labeled [³H] 
estrone-3-sulfate and increasing concentrations of unlabeled estrone sulfate for 3 min 








Figure 4.13 Concentration dependent uptake of estrone-3-sulfate by NTCP. The 
uptake of [
3
H] estrone-3-sulfate was monitored in a buffer system containing 20 nM [
3
H] estrone-
3-sulfate and unlabeled estrone-3 sulfate amounting to a final concentration of 0.1 µM, 0.5 µM, 1 
Concentration of ES (µM)































 = 217.4 µM 
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µM, 10 µM, 50 µM, 100 µM, 250 µM, and 500 µM for 3 min. Net uptake was calculated by 
subtracting the uptake of [
3
H] estrone-3-sulfate in vector cells from the uptake in NTCP-HEK 
cells. Data are represented as means ± SEMs of triplicates. The Km value was calculated from 
three such experiments. The data is expressed as pmol/min/mg of protein.  
4.2.2 Inhibition of NTCP mediated estrone-3-sulfate uptake by antineoplastic 
compounds 
The uptake of [³H] estrone-3-sulfate was measured in the presence of 100 µM of 
antineoplastic compounds for 3 min. Uptake values are represented as % of the uptake of 
substrates in the absence of any antineoplastic compound (buffer control) which was 
determined for NTCP to be 212.2 ± 6.2 pmol estrone-3-sulfate/ 3 min. Only a few 
significant changes in the uptake of [
3
H] labeled estrone-3-sulfate by antineoplastic drugs 
were observed compared to buffer control. 
4.2.2.1 Inhibition of NTCP mediated estrone-3-sulfate uptake by alkylating agents 
The alkylating agents, chlorambucil and busulfan reduced significantly the uptake of 
estrone-3-sulfate by 27.8 ± 2.5 % and 10.2 ± 1.8 %, respectively, whereas an increase in 
the uptake was observed with bendamustine by 20.9 ± 3.9 % of buffer control. No 
significant interactions were observed with the other alkylating agents melphalan, 


















Figure 4.14. Interaction of NTCP with alkylating agents. The uptake of [3H] estrone-3-
sulfate was monitored in a buffer system containing 20 nM [
3
H] estrone-3-sulfate and 19.98 µM 
estrone-3-sulfate in the presence or absence of 100 µM of the respective alkylating compound in 
NTCP transfected HEK cells and vector transfected HEK cells. Data are means ± SEMs of three 
individual experiments with three repeats each. ** represents p value < 0.01, *** represents p 
value < 0.001. 
4.2.2.2 Inhibition of NTCP mediated estrone-3-sulfate uptake by antimetabolites 
None of the antimetabolites tested were able to cause any significant interaction in the 
uptake of NTCP mediated [³H] estrone-3-sulfate (Fig. 4.15). 
 
Uptake of [3H] ES (% of buffer control)




























Figure 4.15. Interaction of NTCP with antimetabolites. The uptake of [3H] estrone-3-
sulfate was monitored in a buffer system containing 20 nM [
3
H] estrone-3-sulfate and 19.98 µM 
estrone-3-sulfate in the presence or absence of 100 µM of the respective antimetabolite in NTCP 
transfected HEK cells and vector transfected HEK cells. Data are means ± SEMs of three 
individual experiments with three repeats each. 
4.2.2.3 Inhibition of NTCP mediated estrone-3-sulfate uptake by intercalating 
agents and mitotic inhibitors 
Among the intercalating agents, mitoxantrone significantly reduced the uptake of NTCP 
mediated estrone-3-sulfate by 10.6 ± 2.4 % whereas doxorubicin did not alter the uptake. 
Among the mitotic inhibitors, vincristine and paclitaxel caused an inhibition of uptake by 
13.7 ± 3 % and 53.3 ± 1.9 % of buffer control, respectively. The other mitotic inhibitor 
tested, vinblastine, did not cause any significant change in the uptake (Fig. 4.16). 
Uptake of [3H] ES (% of buffer control)























Figure 4.16. Interaction of NTCP with intercalating agents and mitotic inhibitors. 
The uptake of [
3
H] estrone-3-sulfate was monitored in a buffer system containing 20 nM [
3
H] 
estrone-3-sulfate and 19.98 µM estrone-3-sulfate in the presence or absence of 100 µM of the 
respective compound in NTCP transfected HEK cells and vector transfected HEK cells. Data are 
means ± SEMs of three individual experiments with three repeats each. ** represents  p value < 
0.01, *** represents p value < 0.001.  
Uptake of [3H] ES (% of buffer control)
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4.2.2.4 Inhibition of NTCP mediated estrone-3-sulfate uptake by topoisomerase 
inhibitors and compounds targeting hormone receptors 
None of the topoisomerase inhibitors or the antineoplastic drugs targeting hormone 
receptors caused any significant interaction to the uptake of estrone-3-sulfate by NTCP-










Figure 4.17. Interaction of NTCP with topoisomerase inhibitors and hormone 
receptor targeters. The uptake of [3H] estrone-3-sulfate was monitored in a buffer system 
containing 20 nM [
3
H] estrone-3-sulfate and 19.98 µM estrone-3-sulfate in the presence or 
absence of 100 µM of the respective compound in NTCP transfected HEK cells and vector 
transfected HEK cells. Data are means ± SEMs of three individual experiments with three repeats 
each.  
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4.3. Interaction of organic anion transporting polypeptide 1B1 (OATP1B1) with 
antineoplastic compounds  
Functionally characterized HEK cells stably expressing OATP1B1 were obtained from 
Dr. Saskia Flörl, PortaCellTec GmbH. Estrone-3-sulfate was used as the substrate for the 
study of transporter activity of OATP1B1. From initial experiments, 5 min was chosen as 
the time of uptake for further experiments and the Km value was calculated to be 0.23 µM. 
So, the inhibition studies were performed with the uptake time of 5 min and the substrate 
concentration of 0.23 µM. 
4.3.1 Inhibition of OATP1B1 mediated estrone sulfate uptake by antineoplastic 
agents 
The uptake of [³H] estrone-3-sulfate was monitored in the presence of 100 µM 
antineoplastic compounds in OATP1B1 expressing cells and vector transfected cells. 
Uptake values are represented as % of the uptake of substrates in the absence of any 
antineoplastic compound which was determined for OATP1B1 to be 118.2 ± 6.5 pmol 
estrone 3- sulfate/ 5 min. The absolute uptake value without drugs in each individual 
experiment was regarded as 100% and uptake under all other conditions is represented as 
percentage of this value. Significant changes were observed in the interaction studies with 
many of the antineoplastic compounds. 
4.3.1.1 Inhibition of OATP1B1 mediated estrone-3-sulfate uptake by alkylating 
agents 
Among the alkylating agents, a weak but significant stimulation of OATP1B1 mediated 
uptake of [³H] estrone-3-sulfate was observed in cells incubated with chlorambucil by 
18.8 ± 2.4 %, cyclophosphamide by 5.6 ± 0.98 %, trofosfamide by 13.1 ± 1.2 %, 
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ifosfamide by 7.4 ± 1.9 % and thio TEPA by 11.9 ± 0.59 %. Any inhibitory effect of 










Figure 4.18 Inhibition of OATP1B1 mediated estrone-3-sulfate uptake by alkylating 
agents. The uptake of [³H] estrone-3-sulfate was followed in the presence of 100 µM of 
alkylating agents. Data is represented as percentage of uptake observed in the absence of any 
compounds and are means ± SEM of three individual experiments with three repeats each. * 
represents p value < 0.05** represents p value < 0.01, *** represents p value < 0.001. 
4.3.1.2 Inhibition of OATP1B1 mediated estrone-3-sulfate uptake by 
antimetabolites 
Among antimetabolites, cladribine alone caused a significant change in the uptake of 
estrone-3-sulfate by OATP1B1; it stimulated the uptake by 15.9 ± 3.8 % of buffer 
Uptake of [³H] ES (% of buffer control)
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control. None of the remaining antimetabolites caused any effect on the OATP1B1 










Figure 4.19 Inhibition of OATP1B1 mediated estrone-3-sulfate uptake by 
antimetabolites. The uptake of [³H] estrone-3-sulfate was followed in the presence of 100 µM 
of antimetabolites. Data is represented as percentage of uptake observed in the absence of any 
compounds and are means ± SEM of three individual experiments with three repeats each. ** 
represents p value < 0.01. 
4.3.1.3 Inhibition of OATP1B1 mediated estrone-3-sulfate uptake by intercalating 
agents and mitotic inhibitors 
The intercalating agents, doxorubicin and mitoxantrone, and the mitotic inhibitor 
vincristine significantly reduced the OATP1B1-mediated uptake of estrone 3- sulfate by 
12 ± 2.2 %, 18.9 ± 2.0 %, and 28.1 ± 1.4 % of buffer control, respectively. The uptake 
Uptake of [³H] ES (% of buffer control)
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was strongly reduced in the presence of the other mitotic inhibitors vinblastine and 










Figure 4.20 Inhibition of OATP1B1 mediated estrone-3-sulfate uptake by 
intercalating agents and mitotic inhibitors. The uptake of [³H] estrone-3-sulfate was 
followed in the presence of 100 µM of intercalating agents and mitotic inhibitors. Data is 
represented as percentage of uptake observed in the absence of any compounds and are means ± 
SEM of three individual experiments with three repeats each. * represents p value < 0.05, *** 
represents p value < 0.001. 
4.3.1.4 Inhibition of OATP1B1 mediated estrone-3-sulfate uptake by 
topoisomerase inhibitors and hormone receptor targeters 
Among the topoisomerase inhibitors, irinotecan caused a profound stimulation of the 
uptake of [³H] estrone-3-sulfate by 93.3 ± 5.0 % of buffer control while incubation with 
Uptake of [³H] estrone sulfate (% of buffer control)
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the compounds prednisone and tamoxifen resulted in a decrease of the uptake by 9.8 ± 
2.7 % and 16.4 ± 3.1 % of buffer control, respectively (Fig. 4.21). Etoposide and 










Figure 4.21 Inhibition of OATP1B1 mediated estrone-3-sulfate uptake by 
topoisomerase inhibitors and hormone receptor targeters. The uptake of [³H] estrone-3-
sulfate was followed in the presence of 100 µM of topoisomerase inhibitors and hormone receptor 
targeters. Data is represented as percentage of uptake observed in the absence of any compounds 
and are means ± SEM of three individual experiments with three repeats each. ** represents p 
value < 0.01, *** represents p value < 0.001. 
Uptake of [³H] ES (% of buffer control)
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4.3.2 Concentration dependent inhibition of antineoplastic compounds on 
OATP1B1 mediated estrone-3-sulfate uptake 
As the two compounds, vinblastine and paclitaxel, strongly inhibited the uptake of 
OATP1B1 mediated estrone sulfate uptake to less than 40 % of buffer control, the kinetic 
constants of inhibition of OATP1B1 were determined for these compounds.  
4.3.2.1 Concentration dependent inhibition of vinblastine on OATP1B1 mediated 
estrone-3-sulfate uptake 
Dixon plot analysis of the uptake of [³H] estrone-3-sulfate in buffer solutions containing 
0.25 µM or 2.5 µM estrone-3-sulfate in the presence of increasing concentrations of 








Figure 4.22 Concentration dependent inhibition of OATP1B1-mediated estrone-3-
sulfate by vinblastine. The uptake of [³H] estrone-3-sulfate was measured in the presence of 0, 
10 µM, 25µM, 50 µM, 75 µM, 100 µM, 125 µM, and 150 µM vinblastine. Dark circles represent 
the uptake values at 0.25 µM estrone-3-sulfate and clear circles represent uptake at 2.5 µM 
Concentration of vinblastine (µM)
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estrone-3-sulfate. Figure is representative and Ki value was calculated from two such experiments. 
Data are means ± SEMs of two independent experiments with three repeats each.  
4.3.2.2 Concentration dependent inhibition of paclitaxel on OATP1B1 mediated 
estrone-3-sulfate uptake 
Dixon plot analysis of the uptake of [³H] estrone-3-sulfate in solutions containing 
0.25 µM or 2.5 µM estrone-3-sulfate in the presence of increasing concentrations of 








Figure 4.23 Concentration dependent inhibition of OATP1B1-mediated estrone-3-
sulfate by paclitaxel. The uptake of [³H] estrone-3-sulfate was measured in the presence of 0, 
0.1 µM, 0.25µM, 0.5 µM, 0.75 µM, 1 µM, 1.5 µM, and 2 µM of paclitaxel. Dark circles represent 
the uptake values at 0.25 µM estrone-3-sulfate and clear circles represent uptake at 2.5 µM 
estrone-3-sulfate. Figure is representative and Ki value was calculated from two such experiments. 
Data are means ± SEMs of two independent experiments with three repeats each.  
Concentration of paclitaxel (µM)
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4.4. Interaction of organic anion transporting polypeptide 1B3 (OATP1B3) with 
antineoplastic compounds 
To study the interactions between the antineoplastic compounds and OATP1B3, initial 
functional characterization was performed with human embryonic kidney cells expressing 
OATP1B3 as a system to measure the transport activity.  
4.4.1 Functional characterization of OATP1B3 transporter activity 
Initial functional characterization of OATP1B3 protein involved time dependent and 
concentration dependent uptake of the radiolabeled substrate cholecystokinin octapeptide 
([³H] CCK-8).  
4.4.1.1 Time dependent uptake of [³H] CCK-8 by OATP1B3 expressing cells  
A time course experiment was performed with OATP1B3 expressing HEK cells and 
vector transfected HEK cells wherein the uptake of [³H] CCK-8 was measured over a 
range of 30 min. From the time course experiments, 2 min was selected for further 
experiments as this was in the linear range of uptake (Fig.4.24).  










Figure 4.24. Time dependent uptake of OATP1B3. Uptake of [³H] CCK-8 was measured 
in buffer containing 5 nM [³H] CCK-8 and 245 nM CCK-8 for 1, 2, 3, 5, 10, 15, 20, and 30 min. 
The net uptake was calculated by subtracting the uptake in vector cells from the uptake in 
OATP1B3 expressing cells and plotted against time. Data are means ± SEMs of three independent 
experiments with three repeats each.  
4.4.1.2 Concentration dependent uptake of [³H] CCK-8 by OATP1B3 expressing 
cells  
The affinity of OATP1B3 was determined by calculating the Michaelis-Menten constant 
Km for the interaction. Measurement of uptake of [³H] CCK-8 in the presence of 
increasing concentrations of unlabeled CCK-8 for 2 min revealed a Km of OATP1B3 for 











































Figure 4.25. Concentration dependent uptake of OATP1B3. Uptake of [³H] CCK-8 was 
measured in buffer solution containing 5 nM [³H] CCK-8 mixed with unlabeled CCK-8 to a final 
concentration of 0.1 µM, 0.25 µM, 0.5 µM, 1 µM, 5 µM, 10 µM, 50 µM and 100 µM for 2 min. 
The net uptake was calculated by subtracting the uptake in vector cells from the uptake in 
OATP1B3 expressing cells and plotted against concentration of CCK-8. Data are means ± SEM 
of three independent experiments with three repeats each. 
4.4.2 Inhibition of OATP1B3-mediated CCK-8 uptake by antineoplastic 
compounds 
The uptake of [³H] CCK-8 was measured in the presence of 100 µM of the corresponding 
antineoplastic compounds in buffer solutions containing 5 nM [³H] CCK-8 mixed with 
995 nM of unlabeled CCK-8 for 2 min. Uptake of [³H] CCK-8 by OATP1B3 in the 
absence of any of the compounds (buffer control) was calculated to be 2.9 ± 0.2 pmol 
CCK-8 / 2 min and the uptake in the presence of any of the antineoplastic compound 
tested is represented as percentage of this value. The uptake was significantly altered in 
the presence of a variety of compounds.  
Concentration of CCK-8 (µM)
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4.4.2.1 Inhibition of OATP1B3 mediated CCK-8 uptake by alkylating agents 
The alkylating agents, bendamustine and chlorambucil significantly reduced the uptake 
by 48.8 ± 2.5 % and 66 ± 1.5 %, respectively, whereas a slight increase in the uptake was 
observed with cyclophosphamide by 8.7 ± 2.0 % of buffer control. There were no 
significant changes observed in the presence of the rest of the alkylating compounds 










Figure 4.26 Inhibition of OATP1B3 mediated CCK-8 uptake by alkylating agents. 
The uptake of [³H] CCK-8 was followed in the presence of 100 µM of alkylating agents. Data is 
represented as percentages of uptake (± SEM) observed in the absence of any compound and are 
means of three individual experiments with three repeats each. ** represents p value < 0.01, *** 
represents p value < 0.001. 
Uptake of [³H] CCK-8 (% of buffer control)
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4.4.2.2 Inhibition of OATP1B3 mediated CCK-8 uptake by antimetabolites 
Among antimetabolites, methotrexate, cytosine arabinoside, gemcitabine, fludarabine, 
and cladribine showed a weak stimulation of the [³H] CCK-8 uptake by 12.0 ± 2.12 %, 










Figure 4.27 Inhibition of OATP1B3 mediated CCK-8 uptake by antimetabolites. The 
uptake of [³H] CCK-8 was followed in the presence of 100 µM of antimetabolites. Data is 
represented as percentage of uptake observed in the absence of any compounds and are means ± 
SEM of three individual experiments with three repeats each. * represents p value < 0.05, ** 
represents p value < 0.01 and *** represents p value < 0.001. 
Uptake of [³H] CCK-8 (% of buffer control)
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4.4.2.3 Inhibition of OATP1B3 mediated CCK-8 uptake by intercalating agents 
and mitotic inhibitors 
The intercalating agents, doxorubicin and mitoxantrone reduced the OATP1B3-mediated 
[³H] CCK-8 uptake by 53.6 ± 1.6 % and 84.4 ± 1.4 % of buffer control, respectively. 
Similarly, the mitotic inhibitors, vincristine, vinblastine and paclitaxel reduced the uptake 











Figure 4.28 Inhibition of OATP1B3 mediated CCK-8 uptake by intercalating agents 
and mitotic inhibitors. The uptake of [³H] CCK-8 was followed in the presence of 100 µM of 
intercalating agents and mitotic inhibitors. Data is represented as percentage of uptake observed in 
the absence of any compounds and are means ± SEM of three individual experiments with three 
repeats each. ** represents p value < 0.01 and *** represents p value < 0.001. 
Uptake of [³H] CCK-8 (% of buffer control)
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4.4.2.4 Inhibition of OATP1B3 mediated CCK-8 uptake by topoisomerase 
inhibitors and hormone receptor targeters 
The topoisomerase inhibitors irinotecan and etoposide reduced [³H] CCK-8 uptake by 
34.3 ± 3.9 % and 76.3 ± 1.6 %, respectively. The uptake of [³H] CCK-8 was reduced by 
12.5 ± 4.4 % in the presence of prednisone and by 38.1 ± 3.9 % in the presence of 










Figure 4.29 Inhibition of OATP1B3 mediated CCK-8 uptake by topoisomerase 
inhibitors and hormone receptor targeters. The uptake of [³H] CCK-8 was followed in the 
presence of 100 µM of topoisomerase inhibitors and compounds targeting hormone receptors. 
Data is represented as percentage of uptake observed in the absence of any compounds and are 
means ± SEM of three individual experiments with three repeats each. * represents p value <0.05, 
** represents p value < 0.01 and *** represents p value < 0.001. 
Uptake of [³H] CCK-8 (% of buffer control)
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4.4.3 Concentration dependent inhibition of antineoplastic compounds on 
OATP1B3 mediated cholecystokinin octapeptide uptake  
From the inhibition experiments, it was observed that chlorambucil, mitoxantrone, 
vinblastine, vincristine, paclitaxel and etoposide inhibited the uptake of OATP1B3-
mediated [³H] CCK-8 uptake to less than 40% of buffer control. So, these cytostatics 
were analyzed further for their inhibition potency by Dixon plot analysis to elucidate the 
affinity of OATP1B3 for them.  
4.4.3.1 Concentration dependent inhibition of chlorambucil on OATP1B3 
mediated CCK-8 uptake 
Measurement of the uptake of [³H] CCK-8 at two different substrate concentrations in the 
presence of increasing concentration of chlorambucil revealed the Ki value to be 








Figure 4.30 Concentration dependent inhibition of OATP1B3 mediated CCK-8 
uptake by chlorambucil. The uptake of [³H] CCK-8 was measured in Hank’s buffer solution 
Concentration of chlorambucil (µM)
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containing 5 nM [³H] CCK-8 and either 995 nM or 9.995 µM unlabeled CCK-8 in the presence of 
0, 10 µM, 25 µM, 50 µM, 75 µM, 100 µM, 125 µM, and 150 µM chlorambucil for 2 min. Dark 
circles represent the uptake values at 1 µM CCK-8 and clear circles represent uptake at 10 µM 
CCK-8. Figure is of one representative experiment and Ki value was calculated from two such 
experiments. Data are means ± SEM of two independent experiments with three repeats each.  
4.4.3.2 Concentration dependent inhibition of mitoxantrone on OATP1B3 
mediated CCK-8 uptake 
The uptake of [³H] CCK-8 measured in buffer solutions containing 1 µM and 10 µM 
CCK-8 in the presence of increasing concentrations of mitoxantrone, revealed a Ki value 








Figure 4.31 Concentration dependent inhibition of OATP1B3 mediated CCK-8 
uptake by mitoxantrone. The uptake of [³H] CCK-8 was measured in Hank’s buffer solution 
containing 5 nM [³H] CCK-8 and either 995 nM or 9.995 µM unlabeled CCK-8 in the presence of 
0, 1 µM, 2 µM, 3 µM, 4 µM, 5 µM, 7.5 µM, and 10 µM mitoxantrone for 2 min. Dark circles 
represent the uptake values at 1 µM CCK-8 and clear circles represent uptake at 10 µM CCK-8. 
Concentration of mitoxantrone (µM)
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Figure is of one representative experiment representative and Ki value was calculated from two 
such experiments. Data are means ± SEM of two independent experiments with three repeats 
each. 
4.4.3.3 Concentration dependent inhibition of vinblastine on OATP1B3 mediated 
CCK-8 uptake 
Dixon plot analysis of the uptake of [³H] CCK-8 in solutions containing 1 µM or 10 µM 
CCK-8 in the presence of increasing concentrations of vinblastine revealed the Ki value of 








Figure 4.32 Concentration dependent inhibition of OATP1B3 mediated CCK-8 
uptake by vinblastine. The uptake of [³H] CCK-8 was measured in Hank’s buffer solution 
containing 5 nM [³H] CCK-8 and either 995 nM or 9.995 µM unlabeled CCK-8 in the presence of 
0, 10 µM, 25 µM, 50 µM, 75 µM, 100 µM, 125 µM, and 150 µM vinblastine for 2 min. Dark 
circles represent the uptake values at 1 µM CCK-8 and clear circles represent uptake at 10 µM 
CCK-8. Figure is representative from one experiment and Ki value was calculated from two such 
experiments. Data are means ± SEM of two independent experiments with three repeats each. 
Concentration of vinblastine (µM)
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4.4.3.4 Concentration dependent inhibition of vincristine on OATP1B3 mediated 
CCK-8 uptake 
Dixon plot analysis of the uptake of [³H] CCK-8 in solutions containing 1 µM or 10 µM 
CCK-8 in the presence of increasing concentrations of vincristine revealed the Ki value of 








Figure 4.33 Concentration dependent inhibition of OATP1B3 mediated CCK-8 
uptake by vincristine. The uptake of [³H] CCK-8 was measured in Hank’s buffer solution 
containing 5 nM [³H] CCK-8 and either 995 nM or 9.995 µM unlabeled CCK-8 in the presence of 
0, 5 µM, 10 µM, 20 µM, 40 µM, 70 µM, 100 µM, and 130 µM vincristine for 2 min. Dark circles 
represent the uptake values at 1 µM CCK-8 and clear circles represent uptake at 10 µM CCK-8. 
Figure is representative from one experiment and Ki value was calculated from two such 
experiments. Data are means ± SEM of two independent experiments with three repeats each. 
Concentration of vincristine (µM)
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4.4.3.5 Concentration dependent inhibition of paclitaxel on OATP1B3 mediated 
CCK-8 uptake 
Measurement of the uptake of [³H] CCK-8 at two different substrate concentrations in the 
presence of increasing concentration of paclitaxel revealed the Ki value to be 1.8 ± 








Figure 4.34 Concentration dependent inhibition of OATP1B3 mediated CCK-8 
uptake by paclitaxel. The uptake of [³H] CCK-8 was measured in Hank’s buffer solution 
containing 5 nM [³H] CCK-8 and either 995 nM or 9.995 µM unlabeled CCK-8 in the presence of 
0, 0.25 µM, 0.5 µM, 1 µM, 2 µM, 3 µM, 4 µM, and 5 µM paclitaxel for 2 min. Dark circles 
represent the uptake values at 1 µM CCK-8 and clear circles represent uptake at 10 µM CCK-8. 
Figure is representative from one experiment and Ki value was calculated from two such 
experiments. Data are means ± SEM of two independent experiments with three repeats each. 
Concentration of paclitaxel (µM)
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4.4.3.6 Concentration dependent inhibition of etoposide on OATP1B3 mediated 
CCK-8 uptake 
Measurement of the uptake of [³H] CCK-8 at two different substrate concentrations in the 
presence of increasing concentration of etoposide revealed the Ki value to be 13.5 ± 








Figure 4.35 Concentration dependent inhibition of OATP1B3 mediated CCK-8 
uptake by etoposide. The uptake of [³H] CCK-8 was measured in Hank’s buffer solution 
containing 5 nM [³H] CCK-8 and either 995 nM or 9.995 µM unlabeled CCK-8 in the presence of 
0, 1 µM, 2.5 µM, 5 µM, 7.5, 10 µM, 15 µM, and 20 µM etoposide for 2 min. Dark circles 
represent the uptake values at 1 µM CCK-8 and clear circles represent uptake at 10 µM CCK-8. 
Figure is representative from one experiment and Ki value was calculated from two such 
experiments. Data are means ± SEM of two independent experiments with three repeats each. 
The results depicted so far highlight the ability of a transporter protein to interact with 
certain antineoplastic compounds that might lead to drug-drug interactions influencing the 
chemotherapy regimens of tumor treatment. There is yet another dimension in which the 
Concentration of etoposide (µM)
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transporter proteins influence the effectiveness of a chemotherapy regimen; their 
expression status in the tumors. Expression of uptake transporters has been shown to vary 
markedly among different tumors. There are many different stages in the metabolism of a 
cell where the expression of a gene is regulated, the other group of experiments are 
focused on the regulation of a transporter protein encoded by the gene SLC22A3; the 
organic cation transporter 3 (OCT3). 
4.5. Expression of SLC22A3 in A498, ACHN, 786-O and LN 78 cells 
Earlier studies conducted in the lab showed a variable expression pattern of OCT3 in 
renal carcinoma cell lines. The current experiments are aimed to find the reason for this 
variable expression of OCT3. The expression pattern found was reestablished prior to 
experiments on the regulation aspects were performed.  
Using TaqMan primers specific for OCT3 and GAPDH, the expression of OCT3 in the 
four renal carcinoma cells was measured. qRTPCR of cDNA prepared from RNA isolated 
from the four cell lines showed a clear pattern wherein the difference between the ΔCt 
value between A498 and ACHN cells was around 12 cycles, consistent with the earlier 
finding in the lab (Fig. 4.36). 




Figure 4.36 Expression of OCT3 in renal carcinoma cell lines. qRTPCR was conducted 
with cDNA prepared from total RNA isolated from the cells. The Ct values of OCT3 and GAPDH 
were obtained and the ΔCt values were obtained by subtracting the Ct (cycle of threshold) of 
GAPDH from the Ct value of OCT3. 
4.6. Effect of inhibition of DNA methylation on expression of OCT3  
To find out whether inhibition of DNA methylation would have any effect on the 
expression of OCT3, cells were treated with 5-aza-2′-deoxy-cytidine, an inhibitor of DNA 
methyltransferase. Incubation of ACHN cells with 5 µM resulted in a decrease of ca. 2 in 
ΔCt value on the expression of OCT3 in these cells. However, there was no further 
increase in the increase of expression of OCT3 with increase in the concentration of 5-
aza-2′-deoxy-cytidine (Fig. 4.37). 




Figure 4.37 Expression of OCT3 in ACHN cells treated with 5-aza-2′-deoxy-cytidine. 
ACHN cells were treated with 5 µM, 15 µM, or 25 µM 5-aza-2′-deoxy-cytidine for 72 h. 
qRTPCR was conducted with cDNA prepared from total RNA isolated from these cells along 
with untreated A498 and ACHN cells. The Ct values of OCT3 and GAPDH were obtained and 
the ΔCt values were obtained by subtracting the Ct (cycle of threshold) of GAPDH from the Ct 
value of OCT3. UT- untransfected, aza-  5-aza-2′-deoxy-cytidine. 
4.7. Effect of inhibition of histone deacetylation on the expression of OCT3 
To find out whether inhibition of acetylation of histones has any effect on the expression 
of OCT3, cells were treated with valproic acid, an inhibitor of the enzyme histone 
deacetylase. Incubation of ACHN cells with 0.5 mM, 5 mM or 10 mM valproic acid for 
24 h did not result in any change in ΔCt value compared to the untreated ACHN cells 
(Fig. 4.38).  




Figure 4.38 Expression of OCT3 in ACHN cells treated with valproic acid. ACHN 
cells were treated with 0.5 mM, 5 mM or 15 mM valproic acid for 24 h. qRTPCR was conducted 
with cDNA prepared from total RNA isolated from these cells along with untreated A498 and 
ACHN cells. The Ct values of OCT3 and GAPDH were obtained and the ΔCt values were 
obtained by subtracting the Ct (cycle of threshold) of GAPDH from the Ct value of OCT3. UT-
untransfected. VPA-valproic acid. 
4.8. Determination of methylation status of CpG islands by Ion-Torrent 
sequencing of bisulfite treated DNA 
The fragments of interest were amplified, from all the cell lines, by PCR using the 
suitable annealing conditions, analyzed on a 2% agarose gel, and the bands were detected 
in a gel documentation chamber (Fig. 4.39). 





Figure 4.39 Amplification of fragments 1 and 2 from the promoter region of 
SLC22A3. The fragments 1 and 2 were amplified using specific primers and analyzed on a 2 % 
agarose gel. Lanes: M-100 bp ladder, 1 - negative control, 2 - A498, 3 - ACHN, 4 - RCCNG-1, 5 - 
786-O, and      6 - LN78. 
 
The obtained fragments were further subjected to adapter PCR wherein they were further 
amplified using specific primers which would make them distinct during the sequencing 
procedure (Fig. 4.40). 
   
Figure 4.40 Adapter PCR of amplified fragments. The fragments 1 and 2 were further 
amplified using specific primers that contained barcode sequences, which make them distinctly 
recognized by the sequencer, and analyzed on a 2 % agarose gel. Lanes: M-100 bp ladder, 1 - 
A498, 2 – ACHN,3 – RCCNG-1, 4 – 786-O, 5 – LN78, 6 – renal epithelial cell pellet, 7 – 
hepatocytes. 
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These fragments were pooled, run on a 2 % agarose gel and extracted from the gel. They 
were quantitated and used to prepare the template positive ion sphere particles which 
were sequenced. The methylation status of the CpG islands in the promoter fragments 1 
and 2 was obtained by comparing the sequence obtained in the ion torrent sequencing run 
with the original sequence of the fragments amplified. There were 15 CpG residues in the 
fragment 1 and they did not show a considerable difference among the renal carcinoma 
cells and the human renal cortical epithelial cell pellet used as a positive control. 
However, there was a considerable difference at the CpG positions 3-7 in LN78 cell line. 
The other CpG islands had similar levels of methylation as the other cell lines. 
The 16 CpG islands in fragment 2 did not show any marked differences between the four 
renal carcinoma cell lines. However, there was a high degree of hypomethylation in the 









Figure 4.41 Analysis of methylation status of CpG islands in fragments 1 and 2 of 
the promoter region of SLC22A3. The fragments 1 and 2 in the promoter region were 
amplified using specific primers and subjected to ion torrent sequencing to analyze the 
methylation status of the CpG islands present in these fragments. The results were downloaded 
from the Torrent server within the program and % methylation of each residue was calculated. 
The % methylation obtained was plotted against the number of CpG residue counted from the 5′ 
end of the template. hRCEPC – human renal cortical epithelial cell pellet. 
 
4.9. qRTPCR of expression of selected microRNAs in A498 and ACHN cells 
From the microRNA predicting programs, 11 microRNA species were selected as they 
were predicted from more than of the stronger prediction programs used for the study. 
qRTPCR of the selected microRNAs in A498 and ACHN cells revealed that two micro 
species hsa-mir-204 and hsa-mir-143 were highly expressed in A498 cells having the 
highest OCT3 expression. The small nucleolar RNAs, RNU48 and RNU43 were used as 
internal controls and ΔCt values were calculated by subtracting the Ct values of these 
RNAs from the corresponding microRNA. 2
-ΔΔCt
 values were calculated by subtracting 
the ΔCt values of microRNAs in ACHN cells from that of the corresponding values in 
A498 cells. There were no microRNA species among the selected microRNAs which was 
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highly expressed in ACHN cells which had low OCT3 expression (Fig.4.42). Two of the 
selected microRNAs did not show any expression in either of the cell lines. 
 
Figure 4.42 qRTPCR of microRNAs in A498 and ACHN cells. The ΔCt values were 
calculated by subtracting the expression of the control RNA (RNU48 and RNU43) from the 
corresponding microRNAs. The ΔΔCt values were obtained by taking A498 cells as reference. 
4.10. Manipulation of levels of hsa-mir-204 and hsa-mir-143 in A498 and ACHN 
cells using microRNA mimics and antimirs 
Transient transfection of microRNA mimics of hsa-mir-204 and hsa-mir-143 into ACHN 
cells led to an increase in the expression of mir-204 and mir-143, respectively; however, 
there was no consequence of this increase of the microRNAs on the expression level of 
OCT3. Similarly, there was a decrease in the expression levels of microRNAs 204 and 
143 in A498 cells upon transfection with corresponding antimirs, but this did not lead to 
any change in the expression of OCT3 in these cells compared to untransfected cells  
(Fig. 4.43). 




Figure 4.43 qRTPCR of SLC22A3 in A498 and ACHN cells upon transfection with 
microRNA mimics and antimirs, respectively. Mimics (m) and antimirs (a) directed 
against microRNAs        hsa-mir-204 and hsa-mir-143 were transiently transfected into A498 and 
ACHN cells. qRTPCR was conducted with cDNA prepared from total RNA isolated from the 
cells. The Ct values of OCT3 and GAPDH were obtained and the ΔCt values were obtained by 
subtracting the Ct (cycle of threshold) of GAPDH from the Ct value of OCT3. UT- untransfected. 
4.11. Genome wide analysis of microRNA in A498, ACHN, 786-O and LN 78 
cells 
Since our earlier approach of using prediction algorithms of microRNA binding to 3′ 
UTR of OCT3 to find out microRNAs potentially involved in regulating the expression of 
OCT3 did not yield a reliable result, we proceeded for the next generation sequencing of 
genome wide microRNA analysis. The run and analysis were performed by our 
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colleagues at the DNA microarray and deep sequencing facility in Goettingen, under the 
supervision of Dr. Gabriela Salinas-Riester. For this purpose, the total RNA was isolated 
from A498, ACHN, 786-O and LN78 cells and subjected to next generation sequencing 
for genome wide analysis of microRNAs in the cells. The sequencing was performed on a 
HiSeq 2000 platform and the results were obtained as microRNA expression in one cell 
line vs microRNA present in another cell line. Many parameters were obtained such as 
mean expression among the triplicates, their ratios, the fold change in logarithmic scale 
with standard error and the significance values of the observed differences in expression 
between two RCCs. 
 
Figure 4.44. Expression patterns of various RNA species in the four cell lines. 
The microRNAs which have a log2 fold change value of more than 2 are presented against each 
comparison of cell lines. The numbers above the bars indicate the total number of microRNAs 
with adjusted p value of < 0.05. The orange and blue bars depict the number of upregulated and 
down regulated microRNAs, respectively, in the cell line (A) in the representation of A vs B. 
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As can be seen in figure 4.44, there is a huge difference of expression of many of the 
small length RNAs among the cell lines. The microRNA species which have a log2 fold 
change of more than 2 are being analyzed further. 
Furthermore, with a focus on ACHN cell line, which has least expression of OCT3, we 
found that a number of microRNAs are highly expressed in this cell line as depicted in 
figure 4.45. 
 
Figure 4.45 Number of microRNAs highly expressed in ACHN (A) and with zero 
expression in LN78 (B), A498 (C) and 7680 (D) cells. 
In addition, there were some microRNAs that were found to be highly expressed in LN78, 
A498, and 786-O cells but not in ACHN cells as represented in figure 4.46 
 
Figure 4.46 Number of microRNAs highly expressed in LN78 (B), A498 (C) and 
7680 (D) cells but not in ACHN (A) cells 




An important step in the elimination of drugs and xenobiotics is the absorption of these 
molecules from blood into the hepatocytes. It is not yet known, how many of the 
antineoplastic agents gain entry into the cells and what are the factors that influence this 
process. The objectives of the study were 1) To find whether the liver specific transporter 
proteins of SLC superfamily are involved in the interaction and eventual uptake of these 
compounds and 2) To understand the mechanisms of regulation of one of the SLC 
protein, the organic cation transporter 3, in renal carcinoma cells.  
5.1. Interaction of OAT2, NTCP, OATP1B1 and OATP1B3 with antineoplastic 
compounds 
The present study is focused on four transporter proteins specifically expressed in the 
liver, organic anion transporter 2 (OAT2), sodium taurocholate cotransporting 
polypeptide (NTCP), and organic anion transporting polypeptides 1B1 (OATP1B1) and 
1B3 (OATP1B3), and tested for their interaction with antineoplastic compounds. For 
studying these interactions, stably transfected human embryonic kidney cells expressing 
the corresponding transporter protein were used. The expression and function of the 
transporter proteins was characterized and used as a platform to study the interactions of 
transporter proteins with antineoplastic agents. The compounds that have been used as 
substrates for the transporter proteins have been described in literature and include cyclic 
guanosine monophosphate (cGMP) for OAT2, estrone-3-sulfate for NCTP and 
OATP1B1, while cholecystokinin octapeptide (CCK-8) was shown to be substrate of 
OATP1B3, respectively [11;152-155]. The Michaelis-Menten constant (Km) values 
generated in our expression systems were in line with the previous observations. We used 
one tenth of the Km values of the model substrate to perform the experiments under 
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standardized conditions for all transporters. Using the uptake of the model substrates in 
the absence of any antineoplastic agent as a reference, we measured the uptake in the 
presence of 100 µM of each one of the compounds. The high concentration of the 
compounds was used to find out any potential interactions. We considered, for kinetic 
analysis, only those interactions which led to an inhibition of the uptake (by100 µM) to 
less than 40% of buffer control. We report, for the first time, a very high affinity of OAT2 
for the antineoplastic drugs bendamustine and irinotecan, apart from a very strong 
interaction with paclitaxel as reported earlier [12]. Dixon plot analysis revealed the Ki 
values of OAT2 for bendamustine, irinotecan, and paclitaxel to be 43.3 ± 4.33 µM, 26.4 ± 
2.34 µM and 10.4 ± 0.45 µM, respectively. None of the antineoplastic compounds studied 
inhibited the uptake of NTCP mediated estrone-3-sulfate to less than 40 % of buffer 
control. Our observation of a strong interaction of OAT2 with paclitaxel is in line with a 
previous report [4] wherein the authors have measured the uptake of radiolabeled 
paclitaxel in OAT2 expressing oocytes. However, we did not see any interaction of OAT2 
with 5-fluorouracil, as observed in the same report. It is not uncommon to see such 
differences in the substrate uptakes between those performed in oocytes and those 
performed in HEK cells or CHO cells. Besides OAT2, paclitaxel is also shown to be 
transported by OATP1B1 and OATP1B3 [156], and our experiments also show strong 
interaction between the two transport proteins and paclitaxel.  
We observed a strong interaction of vinblastine and paclitaxel with OATP1B1. In 
addition, we observed a very strong stimulation of OATP1B1-mediated estrone 3-sulfate 
uptake by irinotecan. Similarly, OATP1B3 showed many significant interactions with the 
antineoplastic compounds tested. This might be an indication of its broad specificity for 
the substrates, and highlights its importance in drug mediated cytotoxicity and drug-drug 
interactions. The compounds chlorambucil, an alkylating agent; mitoxantrone, an 
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intercalating agent; both the vinca alkaloids vincristine and vinblastine and paclitaxel, the 
other mitotic inhibitor tested; and the topoisomerase inhibitor etoposide all strongly 
interacted with varying effectiveness.  
Until recently, there was no study showing any interactions of these antineoplastic agents 
other than paclitaxel with OATP1B1 and OATP1B3. However, in a quest for 
pharmacophore prediction, a study was conducted with as many as 225 drug-like 
compounds in search of their ability to interact with these two proteins [157;158]. 
Although the study was conducted with stably transfected HEK cells as is the case with 
our experiments, there were a number of similarities as well as differences among the 
two. The authors used estradiol-17ß-gulucuronide as a model substrate for OATP1B1 and 
OATP1B3 and 20 µM as the concentration of compounds whose interaction was studied. 
Similar to their observation, we also found comparably strong interactions of OATP1B1 
and OATP1B3 with vinblastine. In addition, we did not find any interaction between 
methotrexate and OATP1B1 as has been previously reported [159]. However, contrary to 
that study, we found a very strong inhibition of OATP1B3-mediated CCK-8 uptake by 
mitoxantrone and etoposide, with Ki values of 15.9 µM and 3.25 µM, respectively, 
suggesting a very high affinity of the transporters for these compounds, apart from 
paclitaxel which seems to be the antineoplastic agent with the highest affinity of all the 
compounds tested in this study. Differences like these have been observed in the past and 
they are shown to arise from the choice of the substrate used in the experiments [160]. 
This is further strengthened by another study wherein the authors used sodium fluorescein 
as a substrate and measured the interactions in Chinese Hamster Ovary cells and observed 
that 10 µM paclitaxel inhibited the OATP1B1 and OATP1B3 mediated uptake of sodium 
fluorescein to 16.4 % and 52.9 % of buffer control, respectively [6]. As mentioned above, 
using estrone-3-sulfate and CCK-8 as substrates, we observed a very strong interaction of 
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paclitaxel with both the OATP transporters with Ki values of 0.84 µM and 1.8 µM, 
respectively.  
Apart from the inhibition of transporter mediated uptake, we also observed stimulation of 
uptake of the corresponding substrates. The most pronounced stimulation was observed in 
the presence of irinotecan on the uptake of estrone 3-sulfate by OATP1B1. Stimulation of 
OATP mediated uptake by another compound has been observed earlier by Wang et al 
similar to our observation of increased estrone 3-sulfate uptake in the presence of 
irinotecan [161;162] and also in the study mentioned above [157;158]. The stimulation 
indicates a complex transport mechanism of OATPs in general and might be due to the 
presence of more than one binding site on OATPs [163]. Most of the interacting 
compounds are bulky and hydrophobic, a feature consistent with the notion that OATPs 
are involved in the transport of such compounds.  
Now that the interactions are established between the antineoplastic compounds and 
OAT2, OATP1B1, and OATP1B3 transporters, more questions arise: firstly, whether 
these interactions lead to drug-drug interactions in vivo and secondly, whether these 
compounds are transported into the cell. To consider the obtained kinetic parameters for 
prediction of in vivo drug-drug interactions, it is necessary to know the unbound fractions 
of the antineoplastic compounds in circulation. The unbound fractions of these 
compounds in circulation were obtained from Goodman and Gilman’s “The 
pharmacological basis of therapeutics” 10
th
 edition and literature [164] and the peak 
plasma concentrations were calculated as per the standard dosages of administration of 
these compounds during the course of chemotherapy.  
The possibility of a compound interacting with OAT proteins to contribute to drug-drug 
interactions in vivo was described previously [66]. Applying the same principle (unbound 
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Cmax/ IC50 ≥ 0.1) to the three inhibitors of OAT2 observed in our study, we found that 
irinotecan has the potential to contribute to drug-drug interactions in vivo, while the 
compounds bendamustine and paclitaxel do not. Similarly, in the case of OATPs, for a 
compound to be possibly involved in drug-drug interaction, it was suggested that the IC50 
value shall be less than or equal to 10 times the unbound Cmax of the drug [66]. Applying 
the same principle with the IC50 values, the antineoplastic compound paclitaxel in the 
case of OATP1B1, and the compounds mitoxantrone, paclitaxel and etoposide for 
OATP1B3 are potential candidates to inhibit the corresponding transporter protein in vivo 
and contribute to drug-drug interactions. The following table summarizes the unbound 
fraction, and the peak plasma concentration of the antineoplastic compounds interacting 























Bendamustine 0.05 14.8 µM 16.88 µM No 
OAT2 
Irinotecan 0.51 2.89 µM 7.55 µM Yes 
OAT2 
Paclitaxel 0.12 0.85 µM 1.44 µM No 
OATP1B1 Vinblastine 0.14 5.75 µM 46.8 µM No 
OATP1B1 Paclitaxel 0.12 0.85 µM 0.28 µM Yes 
OATP1B3 Chlorambucil 0.01 1.67 µM 80.7 µM No 
OATP1B3 
Mitoxantrone 0.25 15.56 µM 3.39 µM Yes 
OATP1B3 
Vinblastine 0.14 5.75 µM 43.5 µM No 
OATP1B3 
Vincristine 0.4 0.56 µM 36.78 µM No 
OATP1B3 
Paclitaxel 0.12 0.85 µM 0.26 µM Yes 
OATP1B3 
Etoposide 0.12 45.8 µM 4.18 µM Yes 
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Table 5.1. Possibility of compounds to contribute to the transporter mediated drug-
drug interactions. 
a
The fraction of compound unbound to protein was obtained from literature 
[164] and from BC cancer agency drug manual. 
b
The peak plasma concentrations were obtained 
from Goodman and Gilman’s “The pharmacological basis of therapeutics” 10
th
 edition and 
literature [165]. 
c
IC50 values were calculated from uptake values measured at 1 µM cGMP 
substrate or 0.25 µM ES or 1 µM CCK-8 as substrate, respectively, in the presence of increasing 
concentration of the corresponding antineoplastic compound. 
d
Possibility of contribution of drug-
drug interactions in vivo is calculated from literature[166]. 
To understand the selectivity of transporter proteins for some of the antineoplastic drugs, 
we analyzed the molecular parameters of the compounds using the MarvinSketch 
software (Tab. 5.2). The obtained parameters logP, logD, polar surface area (psa) and net 
charge at pH 7.4, did not markedly vary among the compounds which interacted with 
OAT2 and the compounds which did not interact. Moreover, the net charge at pH 7.4 of 
bendamustine, irinotecan and paclitaxel was -1, +1 and 0, respectively. In addition, we 
obtained that 87.4 % of vinblastine at pH 7.4 exists in a “+2” ionization state (Table 5.2). 
Likewise, 99.5 % of paclitaxel exists in an uncharged state at the same pH. This is at odds 
with the fact that OATP1B1 interacts with and transports negatively charged species. It 
has also been proposed that high molecular weight (> 300 g/mol) is one of the various 
criteria that are responsible for distinction of a compound to be a substrate of OATPs [6]. 
The fact that both these compounds are bulky high molecular weight molecules (810.9 
g/mol and 853.9 g/mol, respectively) seems to support their candidature. However, the 
selectivity of the protein for vinblastine, but not for vincristine (also a “+2” charged 
compound, with comparable molecular weight of 824.9 g/mol) suggests that there is some 
other specificity factor that drives these interactions.  
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The polar surface area was not markedly different either among the compounds which 
inhibited the transporter activity of OAT2, OATP1B1 or OATP1B3 and those which did 
not (Figure 5.1). Similarly the other parameters like logP value or logD value were not 
considerably different between inhibitors and non-inhibitors and no correlation was 
observed between the parameters obtained from the software and the interactions 
observed. 
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Figure 5.1 Correlation plots of inhibitory effect of antineoplastic compounds and 
their molecular parameters 
Correlation plots of % inhibitory effect of OAT2 mediated cGMP uptake with molecular weights 
(A), polar surface area (at pH 7.4) (B), and logD value (at pH 7.4) of the antineoplastic 
compounds (C); 1, 2 and 3 represent bendamustine, irinotecan and paclitaxel, respectively; 
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OATP1B1 mediated ES uptake with molecular weights (D), polar surface area (at pH 7.4) (E), 
and logD value (at pH 7.4) of the antineoplastic compounds (F); 1, 2, and 3 represent vinblastine, 
paclitaxel and irinotecan, respectively; OATP1B3 mediated CCK-8 uptake with molecular 
weights (G), polar surface area (at pH 7.4) (H), and logD value (at pH 7.4) of the antineoplastic 
compounds;1-chlorambucil, 2-mitoxantrone, 3-vinblastine, 4-vincrsitine, 5-paclitaxel, and 6-
etoposide. 
The other point to understand was whether the interactions observed lead to the uptake of 
these transporters, with a focus on OAT2. As paclitaxel has already been shown to be a 
substrate of OAT2 [12], we concentrated on the other two compounds, bendamustine and 
irinotecan. 
5.1.1 Bendamustine is a substrate of organic anion transporter 2 
As we saw an interaction between the OAT2 and the compounds, bendamustine, 
irinotecan and paclitaxel, we set out to find whether they are inhibitors alone or they can 
be transported by OAT2. Bendamustine is increasingly being recognized as the frontline 
therapy for chronic lymphocytic leukemia (CLL) [167-169] and also in the treatment of 
other lymphomas [170;171]. Structurally bendamustine contains alkylating and 
antimetabolite (purine analog) groups. It belongs to the nitrogen mustard group of 
molecules but its mode of action is predominantly as an alkylating agent, and the 
antimetabolite effect of this compound is not evident yet [172]. As far as we know, there 
is nothing known as to how bendamustine gains entry into the liver cells. Since we did 
not observe any interaction of OAT2 with chlorambucil which is very similar in structure 
to bendamustine or with any of the purine analogs tested, it is not possible with this data 
to conclude which functional group of bendamustine might be responsible for its 
interaction with OAT2. To find whether they are transported by OAT2, we focused on an 
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event that would occur if the antineoplastic drugs use the transporter protein to get into 
the cells, i.e. apoptosis. For measuring OAT2 mediated, bendamustine uptake induced 
apoptosis; we performed the caspase-3 assay wherein the OAT2 expressing cells treated 
with bendamustine showed an increase in the caspase-3 activity compared to the 
untreated OAT2 expressing cells and the control cells with or without treatment. The fact 
that the bendamustine induced increase in caspase-3 activity was diminished almost 
completely in the presence of probenecid demonstrates the specificity of this OAT2 
mediated process. Similar experiments with irinotecan showed a high increase in 
apoptosis in pcDNA as well as OAT2 expressing cells with or without inhibitor, 
suggesting strong OAT2 independent accumulation of the compound in the conditions we 
used. This led us to believe that a protocol needs to be employed which allows the study 
with shorter incubation time.  
5.1.2 Irinotecan is a substrate of organic anion transporter 2 
Irinotecan, also referred to as CPT 11, is a water soluble derivative of camptothecin and a 
well-known topoisomerase inhibitor. It inhibits the topoisomerase I, an enzyme which 
relaxes DNA supercoils formed during the processes of DNA replication and 
transcription, leading to breaks in DNA that result in DNA fragmentation [32]. It is a 
common component of combination chemotherapeutic regimens that are in clinical trials 
for its efficacy in certain cancers like small cell lung cancer, colorectal cancer and 
pancreatic cancer [58;59;173]. There is little information as to how irinotecan is taken up 
into the cell. The active metabolite of irinotecan, SN-38, but not irinotecan as such, was 
shown to be a substrate for the transporter protein OATP1B1 [174]. In our experiments 
we found that it interacted strongly with OAT2, but not with NTCP. We employed HPLC 
analysis as it is highly sensitive and hence can detect irinotecan uptake even at lower 
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incubation periods, as described earlier [175]. A standard curve was developed for 
irinotecan as well as for the internal standard camptothecin and the observed amounts of 
irinotecan in the cell lysates were in the linear range of the curve. An interesting point to 
be noted is that, in our experiments, we did not find any peak for SN38, a hydrolysis 
product of irinotecan, which is the active metabolite of the compound mostly responsible 
for its in vivo activity. Accumulation of irinotecan was observed in both control cells and 
OAT2 expressing cells by HPLC analysis with fluorescence specific detection of 
irinotecan, suggesting a nonspecific accumulation in addition to the transporter mediated 
uptake. However, transporter mediated uptake exceeded the nonspecific accumulation of 
irinotecan in OAT2 expressing cells. This enabled us to determine the affinity (Km) of 
OAT2 for irinotecan, which was determined to be 42.37 µM. In addition, co-incubation of 
irinotecan with 100 µM probenecid did not cause any inhibition on the OAT2 specific 
uptake of irinotecan. In parallel experiments, conducted by a colleague in the department, 
the Ki value of OAT2 for probenecid was determined to be 778.9 µM. This led us to 
believe that as we were working with shorter time periods, we needed a stronger inhibitor 
of OAT2 than probenecid to see a profound effect, and for this reason, we chose 
unlabeled cGMP, the model substrate of OAT2. Inhibition of the accumulation of 
irinotecan in the presence of cGMP in OAT2 expressing cells alone confirmed that this 
increase was transporter specific. This strongly suggests that irinotecan is a substrate of 
OAT2.  
To conclude, the transporters OAT2, OATP1B1 and OATP1B3 interact with many of the 
antineoplastic compounds tested, and there exists a possibility of these transporters to 
contribute to the transporter mediated drug-drug interactions in vivo. As mentioned 
earlier, uptake transporters contribute at the initial stages of absorption, distribution, 
metabolism and excretion (ADME) of an exogenous compound. The uptake transporters 
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expressed in hepatocytes are especially important because liver is the center of xenobiotic 
metabolism. Although there is literature about many of the mechanisms involved in the 
activation of xenobiotic compounds, their interaction with efflux transporters, pathways 
of their excretion, it is not yet known how many of these compounds enter into the cells. 
The current study throws light on the possible roles played by the hepatic uptake 
transporters in the uptake of compounds found to interact with them. The contribution of 
these transporters to such interactions has to be verified in patients, wherein a complex 
network of transporter proteins works in tandem. However, such drug-drug interactions 
exert an influence on the combination chemotherapy of various cancers. Apart from the 
interactions with antineoplastic compounds, the regulation of expression of transporters 
also plays an essential role in the effectiveness of its interacting partner. This fact was 
evident from one of the earlier studies in the department, wherein the uptake of MPP was 
dependent on the level of expression of OCT3 in renal carcinoma cell lines [141]. 
5.2. Regulation of organic cation transporter 3 in renal carcinoma cells 
In the above mentioned study focused on the expression of transporters in the renal 
carcinoma cell lines A498, ACHN, 786-O, RCCNG-1, and LN78, it was found that the 
organic cation transporter 3 (OCT3) was expressed at varying levels. While A498 had 
highest expression of OCT3 among the cell lines, ACHN had the least with 12 cycle 
difference in ΔCt values. The difference between the uptake of the model substrate MPP 
between A498 and ACHN cells was comparable to that observed between OCT3 
transfected Chinese Hamster Ovary (CHO) cells and mock CHO cells. The current study 
is aimed to decipher the possible reasons for this variable expression pattern of OCT3 in 
the renal carcinoma cells. As mentioned in section 1.10, some studies have been 
performed on the expression of OCT3 in other cell systems at the genetic, epigenetic, 
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transcriptional and post-translational levels in various model systems. In the current 
study, we looked at regulation of OCT3 at epigenetic and post-transcriptional levels.  
5.2.1 Epigenetic regulation of OCT3 in renal carcinoma cells 
A decrease in the expression of OCT3 in hepatocellular carcinoma compared to the tumor 
surrounding tissue was reported earlier [145]. Of the epigenetic mechanisms described in 
section 1.9.1, we looked at the impact of histone modification and DNA methylation on 
the expression of OCT3 in renal carcinoma cells. These two modifications play a major 
role in the regulation of gene expression as observed earlier [176]. While histone 
acetylation increases the transcriptional activity of a gene, histone deacetylation and DNA 
methylation reduce its expression. Inhibition of histone deacetylation has been shown to 
promote transcription of a gene. Treatment of cells with inhibitors of histone 
deacetylation was shown to increase the expression of transporters such as excitatory 
amino acid transporter 3 (EAAT3 or EAAC1) encoded by SLC1A1 [177]. 
In order to find out whether the high level of deacetylation of histones is the reason for 
the low expression of OCT3 in ACHN cells, we used valproic acid, an inhibitor of histone 
deacetylases. Treatment of ACHN cells with valproic acid did not change the expression 
level of OCT3 in them, suggesting that histone deacetylation is not the reason for the 
excessively low expression of OCT3 in ACHN cells. Similarly, hypermethylation of 
DNA hinders the transcription of DNA. 5-Aza-2′-deoxycytidine, also known as 
decitabine, is an inhibitor of DNA methyltransferase and treatment of cells with this 
compound was shown to restore the expression of monocarboxylate transporter 3 (MCT3) 
encoded by SLC16A8 [178]. To find out whether hypermethylation of DNA was the 
cause of low expression of OCT3 in ACHN cells, we treated the cells with 5-Aza-2′-
deoxycytidine. Treatment of ACHN cells with 5-Aza-2′-deoxycytidine decreased the ΔCt 
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value by ca. two suggesting an increase of the expression of OCT3; however, this 
increase was not responsive to increasing concentrations of the compound. The increase 
observed does not explain the 12 cycle ΔCt difference observed between A498 and 
ACHN cells. Apart from exerting external perturbations on the possible regulation 
mechanism, we also wanted to know whether the methylation levels of CpG residues in 
the promoter are responsible for this variable expression. To achieve this, we performed a 
next generation sequencing based on bisulfite conversion of unmethylated cytosines to 
uracil, referred to as Ion Torrent Sequencing.  
5.2.2 Impact of methylation of promoter region on the expression of organic 
cation transporter 3. 
Promoter methylation was previously shown to be responsible for the epigenetic down-
regulation of the expression of the uptake transporter organic anion/carnitine transporter 2 
(OCTN2) encoded by SLC22A5, in some cancer cell lines [87]. The down-regulation of 
OCT3 observed in hepatocellular carcinoma compared to the tumor surrounding tissue 
[145] was not due to any difference in the methylation status of the promoter region of 
OCT3 [179]. Methylation status of the promoter regions 1 and 2 of SLC22A3 gene in the 
four cell lines was determined using Ion Torrent sequencing technique. It was clear from 
the results that there was no substantial difference in the methylation patterns in the 
regions 1 and 2 of promoter of OCT3 gene in the CpG residues in the promoter among 
the four cell lines. However the methylation pattern of the positive control, human 
cortical renal epithelial cell pellet was markedly different and showed extensive 
hypomethylation in many of the CpG residues. This observation is in line with the 
observations of a previous study conducted on the promoter of OCT3 in hepatocellular 
carcinomas [179]. In addition, the expression of OCT3 in hepatocellular carcinoma was 
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not markedly different between the normal and tumor tissue, unlike what we observed 
comparing the RCCs with normal kidney cells. From the above results, it must be 
concluded that the epigenetic modifications tested, or the methylation status of promoter 
do not explain for the huge difference of expression of OCT3 between A498 and ACHN 
cells.  
5.2.3 Investigation of microRNA dependent post-transcriptional regulation of 
organic cation transporter 3 
MicroRNAs are being increasingly recognized as regulators of expression of a variety of 
genes and often engage in crosstalk between adjacent pathways. They were shown to 
regulate the expression of transporter proteins as well such as the SLC16A1 gene product, 
monocarboxylate transporter 1 (MCT1) [180]. MicroRNAs have been shown to alter the 
chemotherapeutic potential of antineoplastic compounds [181]. MicroRNAs are a group 
of non-coding RNAs that have been implicated in the regulation of many genes including 
transporters. As the binding of microRNA to its target messenger RNA was found to be 
with incomplete complementarity, programs were developed which use computational 
algorithms to predict possible targets of microRNA in silico. Using strong prediction 
algorithms, supported by correlation studies [117], a data set was generated from 
predicted species using various algorithms which predict microRNAs binding to 3′ 
untranslated region of OCT3 mRNA, and consensus predictions were picked up for 
further analysis. The expression of 11 such microRNA species was obtained by qRTPCR. 
While two of the microRNAs were not expressed quantifiably, there was a differential 
expression of the rest among the cell lines A498 and ACHN. Of these, the microRNAs 
hsa-mir-204 and hsa-mir-143 showed high expression in A498 cell line which had high 
OCT3 expression. This was against to what was expected as the expression of 
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microRNAs was supposed to be in inverse correlation with the expression of their targets. 
Interestingly, hsa-mir-204 was shown to increase the chemosensitivity of neuroblastoma 
cells to cisplatin [181]. However, it has been shown that cisplatin is transported by OCT1 
and OCT2, but not by OCT3 [182]. On the other hand, it was shown to be at least 
partially responsible for cisplatin uptake in human cervical cancer cells [183]. In addition, 
microRNA 204 was implicated as a tumor suppressor [184;185] and maintenance of 
epithelial physiology [186]. Similarly, microRNA 143 was also reported to be a tumor 
suppressor [187;188]. MicroRNA 143 was implicated in conferring chemosensitivity on 
colorectal cancers to oxaliplatin. Although the target was established, the mechanism of 
increase of chemosensitivity has not been explained [189]. It is worthwhile to mention 
here that oxaliplatin was shown to be transported by OCT3 [182].  
The impact of these two microRNAs on the expression of OCT3 was tested by 
experiments which involved altering the levels of microRNA. This was achieved by 
transient transfection of miRNA mimics and antimirs into the cells and any change in the 
expression of OCT3 was monitored by qRTPCR. However, this approach did not work as 
there was no correlation found between the expression levels of microRNAs and OCT3. 
This prompted us to look to other strategies for finding out potential microRNAs that 
could regulate the expression of OCT3, one of which was genome wide analysis of 
microRNA expression. Novel techniques which make the study of genome wide 
expression of microRNAs possible have been recently developed. One such technique, 
the next generation sequencing analysis of genome wide expressed microRNAs was 
performed in the DNA microarray and deep sequencing facility in the university. The 
results were quite encouraging as a lot of microRNA species were found distributed 
among the four cell lines with highly variable expression (ca. 10 cycles). Although there 
are a lot of studies conducted on expression profiling of microRNAs in renal cell 
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carcinoma and the impact of microRNAs on expression of transporters such as the 
glucose transporter 1 (GLUT1) [190], none of them so far were correlated to OCT3 
expression. The genome wide expression analysis we conducted revealed different levels 
of expression of mir-204 and mir-143 compared to our initial observations. This led us to 
believe that a correlation study between the microRNA expression and mRNA expression 
from the same samples would give us more accurate details about the interactions in these 
cells as performed earlier [191]. This is an emerging trend in microRNA research with the 
development of databases such as MIMA (microRNA and mRNA integrated analysis). 
Accordingly, genome wide mRNA analysis is also being performed. Correlation of 
transcriptome analysis with the microRNA data obtained from the samples is the way 
forward to look at candidate genes and microRNAs involved in the regulation of 
expression of OCT3. The entire data shall be correlated with data obtained from healthy 
kidney cells; this approach would help us to look at factors that might regulate the 
expression of OCT3 at the transcriptional as well as post-transcriptional levels. 
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6. Summary and conclusions 
To summarize, we report novel interactions of the SLC transporter proteins expressed in 
liver. Organic anion transporter 2 interacted with the antineoplastic compounds 
bendamustine, irinotecan and paclitaxel. Furthermore, we proved that OAT2 can act as 
transporter for bendamustine and irinotecan. This is a very important observation as this 
is the first report which shows an uptake transporter for bendamustine and irinotecan. 
Irinotecan is metabolized into SN38, which was shown to be a substrate of OATP1B1; 
however, how irinotecan enters the cells is still a question, and our observation of OAT2 
being able to transport irinotecan might provide an answer to this puzzle. We report that 
OATP1B1 interacts strongly with vinblastine and paclitaxel. In addition, OATP1B3 
interacted with the compounds chlorambucil, mitoxantrone, vinblastine, vincristine, 
paclitaxel and etoposide. Other than paclitaxel, it remains to be seen whether these 
compounds are transported by OATP1B1 and OATP1B3. We attempted to understand the 
basis of the differentiation of compounds that interact with those which do not interact 
with the transporter proteins. However, we did not find any correlation between the 
molecular parameters such as molecular weight, polar surface area, logP and logD values 
and the fact whether they interact with a protein or not. From the IC50 values generated, 
we predict whether these interactions might lead to potential drug-drug interactions and as 
per the calculations, the interactions of irinotecan with OAT2, paclitaxel with OATP1B1, 
and the compounds mitoxantrone, paclitaxel and etoposide with OATP1B3 have the 
potential to cause drug-drug interactions and this needs to be looked into in in vivo 
situations. Considering the fact that cancerous tissues exhibit a differential expression of 
transporter proteins, as reported in many cases, the expression of these transporters in 
various cancers also needs to be evaluated. This has the potential to increase the chances 
of a successful chemotherapy many fold. In addition, we also looked at the causes of a 
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variable pattern of expression of OCT3 in the renal carcinoma cell lines A498, ACHN, 
786-O, and LN78, a study reported earlier by our group. We used compounds which 
essentially perturbed the DNA methylation and histone deacetylation mechanisms 
independently, and analyzed their effects on changes of expression of OCT3. We 
observed that these mechanisms could not account for the huge difference of expression 
of OCT3 in A498 (a high OCT3 expressing cell line) and ACHN (a low OCT3 expressing 
cell line). Methylation status of the promoter region of OCT3 was also analyzed and no 
differences were observed among the four RCCs. Using prediction algorithms that predict 
microRNAs able to bind to 3′ UTR of OCT3, we selected those microRNAs which were 
predicted by at least a couple of accurate prediction programs, as reported in the 
literature. The expression of these microRNAs was evaluated in the cell lines A498 and 
ACHN and two microRNAs hsa-mir-204 and hsa-mir-143 were found to be expressed 
more in A498, a cell line with high OCT3 expression. Altering the levels of these 
microRNAs did not affect the expression of OCT3 suggesting that they are not involved 
in the regulation of OCT3. We broadened our search by performing a genome wide 
microRNA analysis in the four RCCs. Many microRNAs are found to be differentially 
expressed in these cell lines and a correlation between the microRNA expression data 
with the transcriptome data is to be done. In this direction, the transcriptome analysis is 
being performed. This strategy shall also shed light on those microRNAs which are 
targeting OCT3 indirectly, along with transcriptional regulators of OCT3.  
To conclude, this study demonstrates for the first time, OAT2 as an uptake transporter for 
bendamustine and irinotecan, antineoplastic compounds widely used in cancer 
chemotherapy. In addition, novel interactions of the antineoplastic compounds with 
OATP1B1 and OATP1B3 are reported. Furthermore, the epigenetic mechanisms of 
histone deacetylation, DNA methylation, and differences in methylation status of CpG 
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residues in the promoter region of OCT3 were not responsible for the differential 
expression of OCT3 in A498 and ACHN cells. A comprehensive approach of next 
generation sequencing of mRNAs of the cell lines is being performed, which in addition 
to the expression data obtained for microRNAs, would be crucial to decipher the 
regulators of OCT3 in renal carcinoma cells.  
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